Harry LeVine, III
Curriculum vitae
August, 2014
Harry LeVine, III
Home Address:
2345 Abbeywood Road
Lexington, KY 40515
Ph. 859-271-4936
Born:
Work Address:
Sanders-Brown Center on Aging
800 S. Limestone Street
Lexington, KY 40536-0230
Ph. 859-218-3329
FAX: 859-3236-2866
Email: hlevine@email.uky.edu
July 12, 1949
Citizenship: United States of America
Married, one child
Education:
9/67-6/71 Cornell University, Ithaca, NY 14850 - B.S./Biochemistry
7/71-8/75
Johns Hopkins University School of Medicine, Dept. of Physiological Chemistry,
725 N. Wolfe Street, Baltimore, MD 21205 - Ph.D/Physiological Chemistry
9/75-8/77
Wellcome Research Laboratories, Dept. of Molecular Biology, 3030 Cornwallis
Road, Research Triangle Park, NC 27709 - Postdoctoral Fellow
Research Interests:
Protein misfolding and aggregation
Neurodegeneration
Protein chemistry and biophysics
Drug discovery and development
Professional Positions:
8/77-10/79 Wellcome Research Laboratories, Dept. of Molecular Biology – Res. Sci. II
10/79-3/82 Wellcome Research Laboratories, Dept. of Molecular Biology - Res. Sci. III
3/82-1/87
Wellcome Research Laboratories, Dept. of Molecular Biology - Res. Sci. IV
2/87-1/91
Glaxo Research Laboratories, Dept. of Structural and Biophysical Chemistry, 5
Moore Drive, Research Triangle Park, NC 27709 - Research Investigator
1/91-3/92
Parke-Davis Pharmaceutical Research Division of Warner- Lambert Co., Dept. of
Neuroscience Pharmacology, 2800 Plymouth Road, Ann Arbor, MI 48106-1047,
Senior Research Associate
Harry LeVine, III
Curriculum vitae
August, 2014
3/92-10/99 Parke-Davis Pharmaceutical Research Division, Dept. of Neuroscience
Therapeutics - Associate Research Fellow
2/94-10/94 Acting Director, Neurodegenerative Diseases Section
10/99-6/00 Parke-Davis Pharmaceutical Research Division, CNS Pharmacology - Research
Fellow
6/00-12/02 Pfizer Global Research & Development, CNS Pharmacology - Research Fellow
1/03 – 7/08
Associate Professor of Molecular & Cellular Biochemistry/Center on Aging,
University of Kentucky, Lexington, KY 40536-0230, tenure-track, full-time
7/08-present Associate Professor of Molecular & Cellular Biochemistry/Center on Aging,
University of Kentucky, Lexington, KY 40536-0230, tenured, full-time
Academic Appointments:
7/89 - 1/91 Adjunct Assistant Professor, Dept. of Neurobiology, Duke University, Durham,
NC 27710, part-time
10/93 – 7/01 Adjunct Assistant Research Scientist, Dept. of Biology, University of Michigan,
Ann Arbor, MI 48109, part-time
1/02 –5/02
Lecturer II, Department of Molecular, Cellular, and Developmental Biology,
University of Michigan, Ann Arbor, MI 48109, part-time
1/03 – 7/08
Associate Professor of Molecular & Cellular Biochemistry/Center on Aging,
University of Kentucky, Lexington, KY 40536-0230, tenure-track, full-time
7/08-present Associate Professor of Molecular & Cellular Biochemistry/Center on Aging,
University of Kentucky, Lexington, KY 40536-0230, tenured, full-time
2/12-6/12
Visiting professor, IFM Dept. of Chemistry, Linkӧping University, Linkӧping,
Sweden
Consultancies:
Consultant and member of Scientific Advisory Board for Alzhyme Pty, Ltd., a start-up
company in Perth, Australia pursuing therapeutic approaches for the prevention of
Alzheimer’s disease.
Consultant and Member of Scientific Advisory Board for Cognition Therapeutics, Inc.,
Pittsburgh, PA pursuing therapeutic approaches to inhibit Aβ oligomer effects on the
brain in Alzheimer’s disease.
Harry LeVine, III
Curriculum vitae
August, 2014
Consultant and Member of Scientific Advisory Board and Drug Safety Monitoring
Board, UK clinical trial, for Alltech, Nicholasville, KY
Consultant for Senexis, Ltd. A startup company in Cambridge, UK, pursuing Aβ
aggregation inhibitors.
Consultant for Acumen Pharmaceuticals. A company in South San Francisco targeting
soluble oligomeric forms of Aβ.
Consultant for the ExoMedicine Institute, a non-profit company in Lexington, KY (part
of KSTC) pursuing medical and other applications of microgravity research.
Member of Scientific Advisory Board Treventis, Inc. A startup company headquartered
in Radnor, PA, pursuing anti-aggregation agents for Aβ and tau.
Professional Service:
Grant ReviewsNIH
ad hoc NINDS NSD-C Jun 06, Nov 06, Feb 07, Jun 07, Oct 07, Mar 08
Charter member NINDS NSD-C (9/12/08 – 6/30/12)
ad hoc ZRG1 BCMB-R41P Special Emphasis Review Panel, P01 review, Nov. 2006
ad hoc NIA ZAG1 ZIJ-7 (J4) Special Emphasis Review Panel, Reverse Site Visit P01 Oct
07, May 08
Special Emphasis Panel NIA P01 review June 2013.
Special Emphasis Panel NIA 2014/10 ZAG1 ZIJ-7 (O1) P01 review June 2014.
EUREKA Special Emphasis Panel ZNS1 SRB N (04) July 2013
Blueprint Alzheimer’s Disease Neurotherapeutics Special Emphasis Panel June 2013
PhRMA Foundation - Section on Basic Pharmacology 2003-present
American Federation for Aging Research (AFAR) National Scientific Advisory Council
member (2011- )
AIRMA, French Alzheimer’s Disease Research Foundation 2005, 2007
Wellcome Foundation 2005, 2013
NHMRC (Australia) 2005
Cottrell Science Award 2006
Alzheimer’s Association 2002, 2004, 2005, 2007, 2008, 2010-2013
Fondazione Telethon Italian Alzheimer’s Disease research foundation 2006
American Cancer Society 2008
Maryland Technology Development Corporation 2010
Medical Research Council (UK) 2013
Foundation for Alzheimer Research (SAO-FRA) 2013
Editorial BoardsFrontiers in Alzheimer’s Disease (2010 - present)
Reviewer for the following journals since coming to UK:
Harry LeVine, III
Amyloid
Analytical Biochemistry
Angewandte Chemie
Archives Biochem Biophys
Biochemistry
Biomolecules
Biophysical Journal
BMC Neuroscience
Brain Research
ChemBioChem
ChemMedChem
Current Neuropharmacology
European J Biophysics
FASEB Journal
Food & Chemical Toxicology
Frontiers of Neurology
Intnl. J. Alzheimer Disease
J. Alzheimer’s Disease
J. American Chemical Society
J. Biological Chemistry
Curriculum vitae
August, 2014
J. Chromatography B
J. Luminescence
J. Medicinal Chemistry
J. Molecular Biology
J. Nanomedicine
J. Neurochemistry
J Neuroscience
J. Neuroimmunology
J. Photochemistry
Molecular Basis of Disease (BBA)
Molecular Pharmacology
Nature Chemical Biology
Nature Protocols
Neurobiology of Aging
Neurobiology of Disease
Neuroscience Letters
Proceedings of the National Academy of Sciences
Protein Expression and Purification
Proteins
Honors:
Fulbright Scholar, Linköping University, Sweden (February – June 2012)
Wethington Award 2007 - 2014
Teaching:
BCH 812 Dental Biochemistry (2003-present); PREP BCH 812 (2008-2010)
BCH 601 General Biochemistry (2003-2012) - Assistant Course Director (2005-2012)
ANA 780 Mechanisms of Neurologic Disease (2009)
BCH 625 Scientific Communications (2010 - present)
BCH 612 Structure and Function of Proteins and Enzymes (2013 – present)
IBS 608 Biochemistry of Neurodegeneration (minicourse, Asst. Course Director, 2014; Course
Director, 2015)
Hon 252 Honors in Arts and Creativity - Creative Nonfiction - Science and Nature Writing for
Young Readers, Course Director, 2015.
GS 600-401 Preparing Future Professionals April 10, 2014
Visiting faculty for the Sea Education Association (Woods Hole, MA) March 27-April 12,
2008 to lecture on Marine Pharmacognosy in Sea Semester C-216 “Documenting Change in the
Caribbean” aboard the oceanographic research sailing vessel Corwith Cramer, Caribbean Sea.
Administrative Activities and University Service:
Committees served on at the University of Kentucky:
Intellectual Property Committee (6/05 - 8/11)
Postdoctoral Advisory Committee (9/06 – present)
Harry LeVine, III
Curriculum vitae
August, 2014
Departmental:
Dept. of Biochemistry Structural Biology Faculty Search (07)
MS/Ph.D. Student Advisory Committees: 2 as primary mentor
MS/Ph.D. Student Advisory Committees: 6 as committee member, + 4 current
Grant Reviews
University of Kentucky Natural Products Alliance 2006
University of Kentucky AMSTEMM 2011
Undergraduate Research and Creativity Grants 2013
Panelist for UK Graduate Student Congress “Careers Outside Academia Panel Discussion”,
April 8, 2014.
University Service Outside of the University of Kentucky (while at UK):
Faculty Mentor for Brian Ciliax, Assistant Professor, Department of Neurology, Emory
University, Atlanta GA.
Ph.D. Student Advisory Committee for Rebecca F. Rosen at Emory University, Atlanta, GA
Ph.D. Student Advisory Committee for Amaryllas F. Cintron at Emory University, Atlanta, GA
Outside Evaluator for Faculty Tenure Decision
University of South Carolina, Dept. of Chemical Engineering, Melissa A. Moss, Ph.D., 2009.
University of Massachusetts, Boston, Dept. of Chemistry, Bela Török, Ph.D., 2010.
Pennsylvania State University Abington College, Dept. of Chemistry, Guiin Lee, Ph.D., 2012.
University of Massachusetts, Boston, Dept. of Chemistry, Marianna Török, Ph.D., 2012.
Publications: (*Authors listed in alphabetical order)
1. LeVine, III, H., Tsong, T.Y., and Hollis, D.P. "Kinetics of Binding of Co+2 to Apoalkaline
Phosphatase from Escherichia coli." Archives of Biochemistry and Biophysics 169: 140145 (1975).
2. LeVine, III, H., Tsong, T.Y., and Hollis, D.P. "Binding of Metal Ions to Apoalkaline
Phosphatase from E. coli: Effect of Ionic Radius." Life Sciences 19: 859-866 (1976).
3. Sahyoun, N.E., Schmitges, C.J., LeVine, III, H., and Cuatrecasas, P. "Molecular
Resolution and Reconstitution of the Gpp(NH)p and NaF Sensitive Adenylate Cyclase
System." Life Sciences 21: 1857-1864 (1977).
4. Hebdon*, G.M., LeVine*, III, H., Schmitges*, C.J., Sahyoun*, N.E., and Cuatrecasas, P.
"Properties of the Interaction of Fluoride and Guanylyl-5'-imidodiphosphate-Regulatory
Proteins with Adenylate Cyclase." Proc. Natl. Acad. Sci. (U.S.A.) 74: 3693-3697 (1978).
5. Hebdon*, G.M., LeVine*, III, H., Minard*, R.B., Sahyoun*, N.E., Schmitges*, C.J., and
Cuatrecasas, P. "Incorporation of Rat Brain Adenylate Cyclase into Artificial Phospholipid
Vesicles." J. Biol. Chem. 254: 10459-10465 (1979).
6. Hebdon*, G.M., LeVine*, III, H., Sahyoun*, N.E., Schmitges*, C.J., and Cuatrecasas, P.
"Demonstration of Choleragen - Dependent ADP-Ribosylation in Whole Cells and
Correlation with the Activation of Adenylate Cyclase."Life Sciences 26: 1385-1396 (1980).
Harry LeVine, III
Curriculum vitae
August, 2014
7. LeVine, III, H., and Cuatrecasas, P. "Activation of Pigeon Erythrocyte Adenylate Cyclase
by Cholera Toxin: Partial Purification of an Essential Macromolecular Factor from Horse
Erythrocyte Cytosol." Biochim. Biophys. Acta 672: 248-261 (1981).
8. Hebdon*, G.M., LeVine*, III, H., Sahyoun*, N.E., Schmitges*, C.J., and Cuatrecasas, P.
"Specific Phospholipids are Required to Reconstitute Adenylate Cyclase Solubilized from
Rat Brain." Proc. Natl. Acad. Sci. (U.S.A.) 78: 120-123 (1981).
9. Sahyoun, N.E., LeVine, III, H., Hebdon, G.M., Khouri, R.K., and Cuatrecasas, P.
"Evidence for Cytoskeletal Associations of the Adenylate Cyclase System Obtained by
Differential Extraction of Rat Erythrocyte Ghosts." Biochem. Biophys. Res. Commun. 101:
1003-1010 (1981).
10. LeVine, III, H., and Cuatrecasas, P. "An Overview of Toxin - Receptor Interactions",
Pharmac. Ther. 12: 167-207 (1981).
11. Sahyoun, N.E., LeVine, III, H., Hebdon, G.M., Hemadah, R., and Cuatrecasas, P. "The
Specific Binding of Solubilized Adenylate Cyclase to the Cytoskeleton." Proc. Natl. Acad.
Sci. (U.S.A) 78: 2359-2362 (1981).
12. Sahyoun, N.E., LeVine, III, H., Davis, J.Q., Hebdon, G.M., and Cuatrecasas, P.
"Molecular Complexes Involved in the Regulation of Adenylate Cyclase." Proc. Natl.
Acad. Sci.(U.S.A.) 78: 6158-6152 (1981).
13. Sahyoun, N.E., Shatila, T., LeVine, III, H., and Cuatrecasas, P. "Cytoskeletal Association
of the Cholera Toxin Receptor in Rat Erythrocytes." Biochem. Biophys. Res. Commun.
102: 1216-1222 (1981).
14. LeVine, III, H., Sahyoun, N.E. and Cuatrecasas, P. "Properties of Rat Erythrocyte
Membrane Cytoskeletal Structures Produced by Digitonin Extraction: Digitonin-Insoluble
β-Adrenergic Receptor, Adenylate Cyclase, and Cholera Toxin Substrate." J. Membrane
Biol. 64: 225-231 (1982).
15. Sahyoun, N., Stenbuck, P., LeVine, III, H., Bronson, D., Moncharmont, B., Henderson, C.,
and Cuatrecasas, P. "Formation and Identification of Cytoskeletal Components from Liver
Cytosolic Precursors." Proc. Natl. Acad. Sci. (U.S.A.) 79: 7341-7345 (1982).
16. Sahyoun, N., LeVine, III, H., Stenbuck, P., and Cuatrecasas, P. "Cytosolic Activator of
Adenylate Cyclase: Reconstitution, Characterization and Mechanism of Action." Proc.
Natl. Acad.Sci. (U.S.A.) 80: 3646-3650 (1983).
17. Sahyoun, N.E., LeVine, III, H., McConnell, R., Bronson, D.D., and Cuatrecasas, P. "A
Specific Phosphatase Acts on Histone H1 Phosphorylated with Protein Kinase C." Proc.
Natl. Acad. Sci. (U.S.A.) 80: 6760-6764 (1983).
18. Sahyoun, N., LeVine, III, H., Bronson, D.D., McConnell, R., and Cuatrecasas, P.
"Histones H3 and H4 Inhibit Protein Kinase C Specifically." Biochem. Biophys. Res.
Commun. 115: 1027-1032 (1983).
19. LeVine, III, H., Bronson, D.D., Khouri, R., and Sahyoun, N.E. "Ascorbic Acid is
Endogenous Cytosolic Inhibitor of ATP - Supported Rat Liver Mitochondrial Calcium
Transport." J. Biol. Chem. 258: 14954-14959 (1983).
20. LeVine, III, H., Sahyoun, N.E., McConnell, R., Bronson, D.D., and Cuatrecasas, P.
"Specificity of a Phosphatase for Phospholipid, Ca+2-Dependent Protein KinasePhosphorylated Histone H1 Resides in the Catalytic Subunit." Biochem. Biophys. Res.
Commun. 118: 278-283 (1984).
21. Sahyoun, N., LeVine III, H., Bronson, D., and Cuatrecasas, P. "Calmodulin-Dependent
Protein Kinase in Neuronal Nuclei." J. Biol. Chem. 259: 9341-9344 (1984).
Harry LeVine, III
Curriculum vitae
August, 2014
22. Sahyoun, N., LeVine, III, H., and Cuatrecasas, P. "The Ca+2-Calmodulin-Dependent
Protein Kinase from the Neuronal Nuclear Matrix and the Postsynaptic Density are
Structurally Related." Proc. Natl. Acad. Sci.(U.S.A.) 81: 4311-4315 (1984).
23. Wolf, M., Sahyoun, N., LeVine, III, H., and Cuatrecasas, P. "Protein Kinase C: Rapid
Enzyme Purification and Substrate - Dependence of the Diacylglycerol Effect." Biochem.
Biophys. Res. Commun. 122: 1268-1275 (1984).
24. Besterman, J.M., May, Jr., W.S., LeVine, III, H., Cragoe, Jr., E.J., and Cuatrecasas, P.
"Amiloride Inhibits Phorbol Ester - Stimulated Na+/H+ Exchange." J. Biol. Chem. 260:
1155-1159 (1985).
25. Sahyoun, N., LeVine, III, H., Bronson, D., Greenstein, F., and Cuatrecasas, P.
"Cytoskeletal Calmodulin - Dependent Protein Kinase: Characterization, Solubilization,
and Purification from Rat Brain." J. Biol. Chem. 260: 1230-1237 (1985).
26. LeVine, III, H., Sahyoun, N., and Cuatrecasas, P. "Calmodulin Binding to the Cytoskeletal
Protein Kinase is Regulated by Autophosphorylation." Proc. Natl. Acad. Sci. (U.S.A.) 82:
287-291 (1985).
27. Sahyoun, N., LeVine, III, H., Burgess, S.K., Blanchard, S.G., Chang, K.-J., and
Cuatrecasas, P. "Early Postnatal Development of Calmodulin-Dependent Protein Kinase in
Rat Brain." Biochem. Biophys. Res. Commun. 132: 878-884 (1985).
28. LeVine, III, H., Sahyoun, N.E., and Cuatrecasas, P. "A Simple and Rapid Assay for Drugs
that Interfere with Calmodulin Function." Anal. Biochem., 151: 153-158 (1985).
29. Wolf, M., LeVine, III, H., May, W.S., Cuatrecasas, P. and Sahyoun, N. "A Model for
Intracellular Translocation of Protein Kinase C Involving Synergism Between Ca+2 and
Phorbol Esters." Nature 317: 546-549 (1985).
30. LeVine, III, H., Sahyoun, N., and Cuatrecasas, P. "Endogenous Dephosphorylation of
Synaptosomal Calmodulin-Dependent Protein Kinase Type II." Biochem. Biophys. Res.
Commun.131: 1212-1218 (1985).
31. Burgess, S.K., Sahyoun, N., Blanchard, S.G., LeVine, III, H., Chang, K.-J., and
Cuatrecasas, P. "Phorbol Ester Receptors and Protein Kinase C in Primary Neuronal
Cultures: Development and Stimulation of Endogenous Phosphorylation." J. Cell Biol.
102: 312-319 (1986).
32. LeVine, III, H., Sahyoun, N.E., and Cuatrecasas, P. "Binding of Calmodulin to the
Neuronal Cytoskeletal Protein Kinase Type II Cooperatively Stimulates
Autophosphorylation." Proc. Natl. Acad. Sci. (U.S.A.), 83: 2253-2257 (1986).
33. LeVine, III, H., Sahyoun, N.E., and Cuatrecasas, P. "Determination of Calmodulin by
Competitive Binding Assay." Anal. Biochem., 152: 183-188 (1986).
34. Sahyoun, N., Wolf, M., Besterman, J., Hsieh, T.-S., Sander, M., LeVine, III, H., Chang, K.J., and Cuatrecasas, P. "Protein Kinase C Phosphorylates Topoisomerase II:
Topoisomerase Activation, and Its Possible Role in Phorbol Ester-Induced Differentiation of
HL-60 Cells." Proc. Natl. Acad. Sci. (U.S.A) 83: 1603-1607 (1986).
35. LeVine, III, H., Cuatrecasas, P., and Sahyoun, N., "Involvement of Fodrin-Binding Proteins
in the Structure of the Neuronal Postsynaptic Density and Regulation by Phosphorylation."
Biochem. Biophys. Res. Commun. 138: 59-65 (1986).
36. Sahyoun, N., LeVine, III, H., McDonald, O.B., and Cuatrecasas, P. "Specific Postsynaptic
Density Proteins bind Tubulin and Calmodulin-Dependent Protein Kinase Type II." J. Biol.
Chem. 261: 12339-12344 (1986).
37. LeVine, III, H. and Sahyoun, N.E. "Characterization of a Soluble Mr 30,000 Catalytic
Harry LeVine, III
Curriculum vitae
August, 2014
Fragment of the Neuronal Calmodulin-Dependent Protein Kinase II." Eur. J. Biochem. 168:
481-486 (1987).
38. LeVine, III, H., and Sahyoun, N.E. "Two types of Brain Calmodulin-Dependent Protein
Kinase II: Morphological, Biochemical, and Immunochemical Properties." Brain Research
439: 47 - 55 (1988).
39. LeVine, III, H., Hunt, D.F., Zhu, N.-Z., and Shabanowitz, J. "Fast Atom Bombardment
Mass Spectroscopic Amino Acid Sequence Analysis of the Neuronal Type II CalmodulinDependent Protein Kinase by Tandem Mass Spectrometry." Biochem. Biophys. Res.
Commun. 148: 1104-1109 (1987).
40. LeVine, III, H., Su, J.-L., and Sahyoun, N.E. "A Monoclonal Antibody Against Brain
Calmodulin-Dependent Protein Kinase Type II Detects Putative Conformational Changes
Induced by Ca+2 and Ca+2-calmodulin." Biochemistry 27: 6612-6617 (1988).
41. LeVine, III, H., Smith, D.P., Whitney, M., Malicki, D.M., Dolph, P.J., Smith, G.F.H.,
Burkhart, W., Zuker, C.S. "Isolation of a Novel Visual System - specific Drosophila
Arrestin: An in vivo Substrate for Light - Dependent Phosphorylation." Mechanisms of
Development 33: 19-26 (1991).
42. Amarant, T., Burkhart, W., LeVine, III, H., Arocha-Pinango, C.L., and Parikh, I. "Isolation
and Complete Amino Acid Sequence of Two Fibrinolytic Serine Proteases from the Toxic
Saturnid Caterpillar Lonomia achelous" Biochimica Biophysica Acta 1079: 214-221 (1991).
43. Lowry, C. L., McGeehan, G, and LeVine, III, H. "Metal Ion Stabilization of the
Conformation of a Recombinant 19 kDa Fragment of Human Fibroblast Collagenase."
Proteins: Structure, Function, and Genetics 12: 42-48 (1992).
44. Burkhart, W., Smith, G. F. H., Parikh, I., and LeVine, III, H. "Amino Acid Sequence
Determination of Ancrod, The Thrombin - like α-Fibrinogenase from the Venom of
Agkistrodon rhodostoma." FEBS Letters 297: 297-301 (1992).
45. Nichols, J.S., LeVine, III, H., Smith, G.F.H., Wypji, D.M., and Wiseman, J.S.
"Determination of Endothelin by an Immobilized Receptor Assay Using a 96-Well Format."
J. Biochem. Biophys. Methods 25: 173-184 (1992).
46. LeVine, III, H. "Thioflavine T Interaction with Synthetic Alzheimer's Disease β - Amyloid
Peptides: Detection of Amyloid Aggregation in Solution.", Protein Science 2: 404-410
(1993).
47. LeVine, III, H. "Soluble Multimeric Alzheimer β(1-40) Pre - Amyloid Complexes in Dilute
Solution.", Neurobiology of Aging 16: 755-764 (1995).
48. LeVine, III, H. "Thioflavine T Interaction with Amyloid β-Sheet Structures." Amyloid:
The International Journal of Experimental and Clinical Investigation 2: 1-6 (1995).
49. Sallese, M., Lombardi, M. S., Haske, T. N., LeVine, III, H., and DeBlasi, A. "Molecular
Analysis of the Functional Role of β- Adrenergic Receptor Kinase 1 Amino Terminal.", J.
Receptor and Signal Transduction Research 15: 81-90 (1995).
50. Mahadevan, D., Thanki, N., Singh, J., McPhie, P., Zangrilli, D., Wang, L.-M., Guerrero,
C., LeVine, III, H., Humblet, Saldanha, J., Gutkind, J.S., and Haske, T. N. "Structural
Studies on the PH Domains of Dbl, SOS1, IRS-1, and βARK1 and their Differential Binding
to Gβγ Subunits.", Biochemistry 34: 9111-9117 (1995).
51. Pumiglia, K. M., LeVine, III, H., Haske, T., Habib, T., Jove, R., and Decker, S. J. "A
Direct Interaction between G-Protein βγ Subunits and the Raf-1 Protein Kinase.", J.
Biol.Chem. 270:14251-14254 (1995).
52. Chuang, T. T., LeVine, III, H., and DeBlasi, A."Phosphorylation and Activation of β-
Harry LeVine, III
Curriculum vitae
August, 2014
adrenergic Receptor Kinase by Protein Kinase C." J. Biol.Chem. 270: 18660-18665 (1995).
53. LeVine, III, H. "Aβ as a Therapeutic Target in Alzheimer's Disease." Current Drugs, ID
Research Alerts; Vol. 1(2) 1-8 (1996).
54. LeVine, III, H. "Stopped-flow Kinetics Reveal Multiple Phases of Thioflavine T Binding to
Alzheimer β(1-40)", Arch. Biochem. Biophys. 342: 306-316 (1997).
55. Haske, T. N., De Blasi, A., and LeVine, III, H. "An Intact N - Terminus of the γ-Subunit is
Required for the Gβγ-mediated Stimulation of Rhodopsin Phosphorylation by Human βAdrenergic Receptor Kinase-1 (βARK1) but not for Kinase Binding.", J. Biol. Chem. 271:
2941-2948 (1996).
56. Wegiel, J., Chauhan, A., Wisniewski, H. M., Nowakowski, J., Wang, K.C., and LeVine, III,
H. "Promotion of Synthetic Amyloid β-Peptide Fibrillization by Cell Culture Media and
Cessation of Fibrillization by Serum.", Neurosci. Lett. 211:151-154 (1996).
57. Sanders, M. A. and LeVine, III, H. "Desensitization of the Neurokinin 1 Receptor is
Mediated by the Receptor Carboxy Terminal Region, but is not Caused by Receptor
Internalization." J. Neurochem. 67: 2362-2372 (1996).
58. Mazur-Kolecka, B., Frackowiak, J., LeVine, III, H., Haske, T., Wisniewski, H. M. "Factors
Produced by Activated Macrophages Reduce Accumulation of Alzheimer's β-Amyloid
Protein in Vascular Smooth Muscle Cells", Brain Res. 760: 255-260 (1997).
59. Fushman, D., Najmabadi-Haske, T., Cahill, S., Zheng, J., LeVine, III, H., and Cowburn D.
"The solution structure and dynamics of the pleckstrin homology domain of G-Protein
Receptor Kinase 2 (βARK1): A Binding Partner of Gβγ Subunits", J. Biol. Chem. 273:
2835-2843 (1998).
60. LeVine, III, H. "Structural Features of Heterotrimeric G-Protein - Coupled Receptors and
their Modulatory Proteins." in Molecular Neurobiology, 19(2):111-149 (1999).
61. Augelli-Szafran, C., Walker, L. C., and LeVine, III, H. “Amyloid as a Target for
Alzheimer’s Disease Therapy.” Annual Reports in Med. Chem. 34:21-30 (1999).
62. LeVine, III, H. "125I-Labeled ApoE Binds Competitively to (1-40) Fibrils with
Pathological Chaperone Proteins", Amyloid: The International Journal of Experimental and
Clinical Investigation, 7: 83-89 (2000).
63. Walker, L. C. and LeVine, III, H. "The cerebral proteopathies", Neurobiology of Aging 21:
559-561 (2000).
64. Walker, L. C. and LeVine, III, H. "Protein conformational diseases: the case for new
semantic currency" Neurobiology of Aging 21: 567 (2000).
65. Wegiel, J., Wang, K.-C., Imaki, H., Rubenstein, R., Wronska, A., Osuchowski, M., Lipinski,
W.J., Walker, LC., LeVine, III, H. “The role of microglial cells and astrocytes in fibrillar
plaque evolution in transgenic APPsw mice”, Neurobiology of Aging 22: 49-61 (2001).
66. Walker, L. C. and LeVine, III, H. “The Cerebral Proteopathies: Neurodegenerative
Disorders of Protein Conformation and Assembly”, Molecular Neurobiology 21(1/2) 83-95
(2001).
67. LeVine, III, H. and Walker, L. C. "Cerebral Proteopathies and the Inhibition of A
Fibrillogenesis in Alzheimer’s Disease." Research and Practice in Alzheimer's Disease and
Other Dementias 6: 27-31 (2002), Hopitaux de Toulouse, Toulouse FRANCE.
68. LeVine, III, H. "The Challenge of Inhibiting A Fibrillogenesis”, Current Medicinal
Chemistry 9(11): 1121-1133 (2002).
69. LeVine, III, H. “4, 4’-dianilino-1, 1’-binaphthyl-5, 5’-disulfonate (bis-ANS) Reports on
Non--Sheet Conformers of Alzheimer’s Peptide (1-40)”, Arch. Biochem. Biophys. 404:
Harry LeVine, III
Curriculum vitae
August, 2014
106-115 (2002).
70. Walker, L.C., Bian, F., Callahan, M. J., Lipinski, W. J., Durham, R. A., and LeVine, III, H.
“Modeling Alzheimer’s Disease and Other Proteopathies In Vivo: Is Seeding the Key?”,
Amino Acids 23: 83-88 (2002).
71. Walker, L. C. and LeVine, III, H. “Proteopathy: The Next Therapeutic Frontier?”, Current
Opinion in Investigational Drugs 3(5): 782-787 (2002).
72. LeVine, III, H. “Y10W (1-40) Fluorescence Reflects Epitope Exposure in Conformers of
Alzheimer’s β-Peptide”, Arch. Biochem. Biophys. 417: 112-122 (2003).
73. LeVine, III, H. “Challenges of Targeting A Fibrillogenesis and Other Protein Folding
Disorders”, Amyloid: The Journal of Protein Folding Disorders, 10: 133-135 (2003).
74. Mazur-Kolecka, B., Frackowiak, J., LeVine, III, H., Haske, T., Evans, L., Sukontasup, T.,
and Golobek, A. “TGF1 Enhances formation of cellular A /ApoE deposits in vascular
myocytes”, Neurobiology of Aging 24: 355-364 (2003).
75. Fowler, C. B., Pogozheva, I. D., LeVine, H., III, and Mosberg, H. I. “Refinement of the
Homology Model of -Opioid Receptor Using Distance Constraints from Natural and
Artificial Zinc-Binding Sites”, Biochemistry, 43(27): 8700-8710 (2004).
76. Fowler, C. B., Pogozheva, I. D., Lomize, A. L., LeVine, H., III, and Mosberg, H. I.
“Complex of Active -Opioid Receptor with a Cyclic Peptide Agonist Modeled From
Experimental Constraints”, Biochemistry, 43(50):15796-15810 (2004).
77. Sweeney, D., Zhou, Z., Martins, R., LeVine, H., III, Smith, J. D., and Gandy, S., “Similar
Promotion of A-beta(1-42) Fibrillogenesis by Native Apolipoprotein E epsilon3 and
epsilon4 Isoforms”, J. Neuroimmunology, 1: 15-19 (2004).
78. LeVine, III, H. “Alzheimer’s β -Peptide Oligomer Formation at Physiologic
Concentrations”, Analyt. Biochem. 335: 81-90 (2004).
79. LeVine, III, H. “The Amyloid Hypothesis and the Clearance and Degradation of
Alzheimer’s β-Peptide”, J. Alzheimer’s Disease 6: 303-314 (2004).
80. Walker, L. C., Ibegbu, C. C., Todd, C. W., Robinson, H. L., Jucker, M., LeVine, III, H. and
Gandy, S. “Emerging Prospects for the Disease-Modifying Treatment of Alzheimer's
Disease”, Biochemical Pharmacology, 69: 1001-1008 (2005).
81. Frackowiak, J., Potempska, A., LeVine, III, H., Haske, T., Dickson, D., and MazurKolecka, B., “Extracellular Deposition of Aβ in Cultures of Alzheimer’s Disease Brain
Vascular Smooth Muscle Cells”, J. Neuropathol. Exptl. Neurol. 64:82-90 (2005).
82. LeVine, III, H. “Multiple Ligand Binding Sites on Aβ(1-40) Fibrils” – Amyloid: The
Journal of Protein Folding Disorders, 12: 5-14 (2005).
83. LeVine, III, H., “Mechanism of A(1-40) Fibril-induced Fluorescence of (trans, trans)-1bromo-2,5-bis(4-hydroxy)styrylbenzene (K114)”, Biochemistry 44: 15937-15943 (2005).
84. Walker, L. C., LeVine, III, H., and Jucker, M. "Koch's Postulates and Infectious Proteins”,
Acta Neuropathologica, 112(1): 1-4 (2006).
85. Walker, L. C. LeVine, III, H., Mattson, M. P., and Jucker, M. “Inducible Proteopathies”,
Trends in Neuroscience 29: 438-443 (2006).
86. LeVine, III, H. “A Biotin-Avidin Based Screening Assay for Aβ Peptide Oligomer
Inhibitors”, Anal. Biochem. 356: 265-272 (2006).
87. LeVine, III, H. “Small Molecule Inhibitors of Aβ Assembly”, Amyloid: The Journal of
Protein Folding Disorders, 14(3):185-197 (2007). PMID: 17701466
88. Murphy, M. P., Beckett, T. L., Ding, Q., Markesbery. W. R., St. Clair, D. K., Flood, D. G.,
LeVine, III, H., and Keller, J. N. “Aβ solubility and deposition during AD progression and
Harry LeVine, III
Curriculum vitae
August, 2014
in APP X PS-1 knock-in mice”, Neurobiology of Disease, 27(3): 301-311 (2007). PMID:
17651976, NIHMS30584.
89. Walker, L. C., Rosen, R. F., and LeVine, III, H. “Diversity of Aβ Deposits in the Aged
Brain: A Window on Molecular Heterogeneity?” Romanian J. Morph. Embryol. 49(1): 5-11
(2008). PMID: 18273496
90. Simons, L. J., Augelli-Szafran, C. E., Caprathe, B. W., Callahan, M., Graham, J. M.,
Kimura, T., Lai, Y., LeVine, III, H., Lipinski, W., Sakkab, A. T., Tasaki, Y., Walker, L.
C., Yasunaga, T., Ye, Y., Zhuang, N. “The Synthesis and Structure-Activity Relationship of
Substituted N-Phenyl Anthranilic Acid Analogs as Amyloid Aggregation Inhibitors”,
Bioorganic & Medicinal Chemistry Letters, 19: 654-657 (2009). PMID: 19121939
91. LeVine, III, H. and Walker, L. C. “Molecular Polymorphism of Aβ in Alzheimer’s Disease
Plaques”, Neurobiology of Aging, 31: 542-548 (2010).
doi:10.1016/j.neurobiolaging.2008.05.026. PMID: 18619711, PMC2842206
92. Rosen, R. F., Walker, L. C., and LeVine, III, H. “PIB Binding in Aged Primate Brain:
Unique Enrichment of High Affinity Sites in Humans with AD", Neurobiology of Aging 32:
223-234 (2011). doi:10.1016/j.neurobiolaging.2009.02.011, PMC2891164
93. LeVine, III, H., Ding, Q., Walker, J. A., Voss, R. S., and Augelli-Szafran, C. E.
“Clioquinol and other hydroxyquinoline derivatives inhibit Aβ(1–42) oligomer assembly”,
Neurosci. Lett. 465: 99-103 (2009). doi: 10.1016/j.neulet.2009.08.002, PMC2754118
94. Abdul, H. M., Sama, M. A., Furman, J. L., Patel, E. S., Beckett, T. L., Weidner, A. M.,
Murphy, M. P., LeVine III, H., Krainer, S. D., and Norris, C. M. “Cognitive decline in
Alzheimer’s disease is associated with selective changes in calcineurin/NFAT signaling”, J.
Neurosci., 29(41):12957-12969 (2009). PMID: 19828810, PMC2782445
95. Murphy, M. P. and LeVine, III, H., “Alzheimer’s Disease and the β-Amyloid Peptide”, J.
Alzheimer’s Disease 19(1): 311-323 (2010). PMID: 20061647, PMC2813509
96. Rosen, R. F., Ciliax, B. J., Gearing, M., Dooyema, J., Wingo, T. S., Lah, J. J., Ghiso, J.,
LeVine, III, H., Walker, L. C. “Deficient High-Affinity Binding of Pittsburgh Compound
B in a Case of Alzheimer's Disease”, Acta Neuropathologica, 119: (2) 221-233 (2010)
PMID: 19690877, PMC3045810
97. Bruce-Keller, A. J., Gupta, S., Parrino, T. E., Knight, A. G., Ebenezer, P. J., Weidner, A.
M., LeVine, III, H., Keller, J. N., and Markesbery, W. R. “NOX Activity is Increased in
Mild Cognitive Impairment”, Antioxidants and Redox Signaling, 12(12): 1371-1382 (2010).
PMID 19929442, PMC2864654
98. Murphy, M. P., Morales, J., Beckett, C. L., Astarita, G., Piomelli, D., Weidner, A.,
Studzinski, C. M., Dowling, A., L., S., Wang, X., LeVine, III, H., Kryscio, R. J., Lin, Y.,
Barrett, E., and Head, E. “Changes in Cognition and Aβ Processing with Long Term
Cholesterol Reduction using Atorvastatin in Aged Dogs”, J. Alzheimer’s Disease, 22: 135150 (2010). PMID 20847439
99. Beckett, T. L., Niedowicz, D. M., Studzinski, C.M., Weidner, A. M., Webb, R. L., Holler,
C. J., Ahmed, R. R., LeVine, III, H., and Murphy, M. P. “Effects of Nonsteroidal AntiInflammatory Drugs on Amyloid-β Pathology in Mouse Muscle”, Neurobiology of Disease,
39: 449-456 (2010). PMID 20493261, PMC2910117
100. Abdul, H. A., Baig, I., LeVine, III, H., Guttmann, R. P., and Norris, C. M. “Calpainmediated Proteolysis of Calcineurin is Increased in Hippocampus During Mild Cognitive
Impairment and is Stimulated by Oligomeric Abeta”, Aging Cell, 10(1) 103-113 (2010).
PMID 20969723, PMC3021581
Harry LeVine, III
Curriculum vitae
August, 2014
101. Ebenezer, P. J., Weidner, A. M., LeVine, III, H., Markesbery, W. R., Murphy, M. P.,
Zhang, Le, Dasuri, K., Fernandez-Kim, S. O., Bruce-Keller, A. J., Gavilán, E., and Keller, J.
N. “Neuron specific toxicity of oligomeric beta amyloid: Implications for JUN-kinase and
oxidative stress”, J. Alzheimer’s Disease, 22(3): 839-848 (2010). PMID 20858948,
PMC3412400.
102. Niedowicz, D. M., Beckett, T. L., Matveev, S., Weidner, A. M., Baig, I., Abner, E. L.,
Kryscio, R. J., Mendiondo, M. S., LeVine, III, H., Keller, J. N., and Murphy, M. P.
“Pittsburgh Compound B and the Postmortem Diagnosis of Alzheimer’s Disease”, Annals
of Neurology, 72(4): 564-570 (2012). PMID: 23109151, PMC3490445.
103. Weidner, A. M., Housley, M., Murphy, M. P, and LeVine, III, H. “Purified High Molecular
Weight Synthetic Aβ(1-42) and Biological Aβ Oligomers are of Comparable Potency in
Rapidly Inducing MTT Formazan Exocytosis”, Neurosci. Lett., 497(1): 1-5 (2011). PMID
21504780, PMC3110692.
104. LeVine, III, H., Lampe, L., Abdelmoti, L., and Augelli-Szafran, C. E. “Dihydroxybenzoic
Acid Isomers Differentially Dissociate Soluble Biotinyl-Aβ(1-42) Oligomers”,
Biochemistry, 51(1): 307-312 (2012). PMID: 22129351, PMC4006955
105. Cenini, G., Dowling, A. L. S., Beckett, T., Barone, E., Mancuso, C., Murphy, M. P., LeVine
III, H., Schmitt, F. A., Butterfield, D. A, and Head, E. “Association between frontal cortex
oxidative damage and beta-amyloid neuropathology as a function of age in Down
syndrome”, BBA- Molecular Basis of Disease, 1882: 130-138 (2012). PMID: 22009041,
PMC3260028.
106. Weidner, A. M., Bradley, M. A., Beckett, T. L., Niedowicz, D. M., Dowling, A. L. S.,
Matveev, S. V., LeVine, III, H., Lovell, M. A., and Murphy, M. P., “The RNA oxidation
adducts 8-OHG and 8-OHA change with Aβ42 levels in late-stage Alzheimer's Disease”,
PLoS One 6(9): e24930 (2011). PMID: 21949792, PMC3176793.
107. Rosen, R. F., Fritz, J. J., Dooyema, J., Cintron, A. F., Hamaguchi, T., Lah, J.J., LeVine, III,
H., Jucker, M., and Walker, L.C., entitled "Exogenous seeding of cerebral β-amyloid
deposition in βAPP-transgenic rats", J. Neurochemistry, 120(5):660-666 (2012). PMID:
22017494 PMC3293176
108. Török, B., Sood, A., Bag, S., Kulkarni, A., Borkin, D., Lawler, E., Dasgupta, S., Landge, S.,
Abid, M., Foster, M., LeVine, III, H., and Török, M., “Structure activity relationship of
organofluorine inhibitors of amyloid-beta self assembly”, ChemMedChem, 7(5):910-919
(2012). PMID:22351619, NIHMS384956.
109. Beckett, T. L., Webb, R. L., Niedowicz, D. M., Holler, C. J., Matveev, S., Baig, I., LeVine,
III, H., Keller, J. N., and Murphy, M. P. “Postmortem Pittsburgh Compound B (PiB)
Binding Increases with Alzheimer’s Disease Progression”, J. Alzheimer’s Disease, 32 (1):
127-138 (2012). PMID: 22766739, PMC3607315.
110. Török, B., Sood, A., Bag, S., Agarwalla, R., Borkin, D., Kennedy, A. R., Melanson, M.,
Madden, R., Zhou, W., LeVine, III, H., and Török, M. “Diaryl Hydrazones as Multitarget
Inhibitors of Amyloid Self-Assembly”, Biochemistry, 52(7): 1137–1148 (2013). PMID:
23346953, PMC3608202.
111. Walker, L. C. and LeVine, III, H. “The corruption and spread of pathogenic proteins in
neurodegenerative diseases” (invited minireview), J. Biol. Chem. 287 (40): 33109-33115
(2012). PMID: 22879600, PMC3460416.
112. Bag, S. Tulsan, R., Sood, A., Ghosh, S., Zhou, W., Schifone, C., Foster, M., LeVine III, H.,
Török, B., and Török, M. “Design, Synthesis and Biological Activity of Multifunctional α,β-
Harry LeVine, III
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
Curriculum vitae
August, 2014
Unsaturated Carbonyl Scaffolds for Alzheimer’s Disease”, Bioorg Med Chem Lett.
23(9):2614-2618 (2013). PMID: 23540646, PMC3676911
Zhang, L., Dasuri K., Fernandez-Kim, S.-O., Bruce-Keller, A. J., Freeman, L. R., Pepping,
J. K., LeVine, III, H., Beckett, T. L., Murphy, M. P., and Keller, J. N. “Prolonged Diet
Induced Obesity Has Minimal Effects Towards Brain Pathology In Mouse Model of
Cerebral Amyloid Angiopathy: Implications for Studying Obesity-Brain Interactions In
Mice”, BBA-Molecular Basis of Disease, 1832(9): 1456-1462 (2013). PMID: 23313575
Matveev, S. V., Spielmann, H. P., Metts, B. M., Chen, J., Onono, F., Zhu, H., Scheff, S. W.,
Walker, L. C., and LeVine, III, H. “A Distinct Subfraction of Aβ is Responsible for the
High-Affinity Pittsburgh Compound B (PIB) Binding Site in Alzheimer’s Disease Brain”, J.
Neurochemistry, in press, NIHMS611505 doi: 10.1111/jnc.12815 PMID: 24995708
Baig, I. and LeVine, III, H. “sRAGE Domain Interactions with Aβ and tau oligomers”, in
preparation
Qosa, H., LeVine, III, H., Keller, J. N., and Kaddoumi, A. “Mixed Oligomers and
Monomeric Amyloid-β Disrupts Blood-Brain Barrier Integrity and Reduces Monomeric
Amyloid-β Clearance”, BBA - Molecular Basis of Disease PMID 24997450
Izzo, N. J., Staniszewski, A., To, T., Fá, M., Teich, A. F., Saeed, F., Wostein, H., Walko,
III, T., Vaswani, A., Wardius, M., Syed, S., Ravenscroft, J., Mozzoni, K., Silky, C., Rehak,
C., Yurko, R., Finn, P., Look, G., Rishton, G., Safferstein, H., Miller, M. C., Johanson, C.
E., Stopa, E. G., Windisch, M., Hutter-Paier, B., Shamloo, M., Arancio, O., LeVine, III, H.,
and Catalano, S. M. “Small Molecule Therapeutic Candidates for Alzheimer's Disease act as
Pharmacological Antagonists of Amyloid Beta Oligomers”, submitted
Izzo, N. J.; Xu, J., Zeng, C., Kirk, M., Mozzoni, K., Silky, C., Rehak, C., Yurko, R., Look,
G., Rishton, G., Safferstein, H., Cruchaga, C., Goate, A., Cahill, M., Arancio, O., Mach, R.
H., Craven, R., Head, E., LeVine, III, H., Spires-Jones, T. L., and Catalano, S. M. “Sigma2/PGRMC1 Receptors Mediate Amyloid Beta 1-42 Oligomer Binding, Synaptotoxicity, and
Memory Failure”, submitted
Matveev, S. V., Kwiatkowski, S., Sviripa, V. M., Fazio, R. J., Watt, D. S., and LeVine, III,
H. “Tritium-labeled (E,E)-2,5-Bis(4’-hydroxy-3’-carboxystyryl)benzene as a Probe for βAmyloid Fibrils”, submitted
Bag, S., Tulsan, R., Sood, A., Cho, H., Redjeb, H., Zhou,W., LeVine, III, H., Marianna
Török, M., and Török, B., “Design and Synthesis of Sulfonamides as Multi-functional
Agents for Alzheimer’s Disease”, submitted
Zhang, X., Lu, W., Ye, C., LeVine, III, H., and Wei, Y., “Characterization of S. aureus
family II pyrophosphatase PpaC and the functional relevance of dimerization”, submitted
Rosen, R. F., Farberg, A. S., Dooyema, J., Demuth (?), H.-U., Tomidokoro (?), Y., Ciliax
(?), B., Gearing, M., Preuss, T. M., Ghiso, J. A., LeVine, III, H., and Walker, L. C.,
“Characterization of Aβ peptide populations in aged human and nonhuman primate brain”,
in preparation
Chapters, Books: (*Authors listed in alphabetical order)
1. Pedersen, P.L., LeVine, III, H., and Cintron, N. "Activation and Inhibition of
Mitochondrial ATPase of Rat Liver Mitochondria" in Membrane Proteins in Transport and
Phosphorylation, G.F. Azzone, M.E. Klingenberg, E. Quagliariello, and N. Siliprandi (eds.)
North Holland Publishing Company, Amsterdam, c. 1974 pp. 43-54.
2. Sahyoun, N.E., Schmitges, C.J., LeVine, III, H., and Hebdon, G.M. "Receptors: an
Harry LeVine, III
Curriculum vitae
August, 2014
overview." in Frontiers of Knowledge in the Diarrheal Diseases - International Colloquium
in Gastroenterology, Janowitz, H.D., and Sachar, D.M. (eds.) Projects in Health, Inc., Upper
Montclair, N.J. c. 1979, pp. 85-111.
3. Hebdon*, G.M., LeVine*, III, H., Sahyoun*, N.E., Schmitges*, C.J., and Cuatrecasas, P.
"Some Perspectives on the Hormone-Stimulated Adenylate Cyclase System." Receptors
and Recognition Series B, 11: 205-236 (1981).
4. LeVine, III, H., Sahyoun, N.E., and Cuatrecasas, P. "Architecture of Plasma Membrane
Hormone Receptor-Effector Systems." in Methodological Surveys in Biochemistry and
Analysis Reid, E., Cook, G.M.W. and Moore, D.J. (eds), 13: 163-180 (1984).
5. LeVine, III, H., Sahyoun, N., and Cuatrecasas, P. "Protein Phosphatase-Mediated Reversal
of Ca+2-Dependent Protein Phosphorylation.", Adv. Prot. Phosphatases I: 383-397 (1985).
6. LeVine, III, H. and Cuatrecasas, P. "An Overview of Toxin - Receptor Interactions." in
International Encyclopedia of Pharmacology and Therapeutics, Volume entitled
"Pharmacology of Bacterial Toxins" Dorner, F. and Drews, J. (eds) Section 119, pp. 31-76.
Pergamon Press (1986).
7. LeVine, III, H. and Sahyoun, N.E. "Neuronal Signaling: Pathways and Protein Kinases." in
Developmental Neurobiology of Breathing, Haddad, G. G., Farber, J.P. (eds), Vol. 53: 71110, Marcel Dekker Press (1991).
8. LeVine, III, H. and Brown, S. "Advances in Receptor Investigation 1980-1990." in
Methodological Surveys in Biochemistry and Analysis; Cell Signalling: Experimental
Strategies, Vol. 21: 13-30, Reid, E., Cook, G.M.W., and Luzio, J.P. (eds), Royal Society of
Chemistry (1991).
9. LeVine, III, H. "A/β Fibril Formation as a Therapeutic Target" in Alzheimer's Disease.
Advances in Diagnostics and Drug Development, (Conference Proceedings), Emory, K.(ed),
IBC Biomedical Library Series, Southborough, MA, pp. 4.1.1-4.1.17 (1996).
10. Fowler, C. B., LeVine, III, H., and Mosberg, H. I. "Examination of the Role of TMH-VII in
Subtype-Selective Ligand Binding using Semisynthetic Muscarinic Receptors." Peptides.
Frontiers of Peptide Science, 15th American Peptide Symposium, Tam, J.P., and Kaumaya,
P.T.P.(eds), Kluwer Academic Publishers, Dordrecht, Netherlands, pp. 586-587 (1998).
11. LeVine, III, H. "Quantification of -Sheet Amyloid Fibril Structures with Thioflavin T."
Meth. Enzymol. 309: 274-284 (1999).
12. LeVine, III, H. and Scholten, J. D. "Screening for Pharmacologic Inhibitors of Amyloid
Fibril Formation." Meth. Enzymol. 309: 467-476 (1999).
13. Emmerling, M., Spiegel, K., Hall, E. D., LeVine, III, H., Walker, L., Schwarz, R.D., and
Gracon, S. “Emerging Strategies for the Treatment of Alzheimer’s Disease at the
Millenium.” in Emerging Drugs, The Prospect for Improved Medicines, pp. 35-86, Ashley
Publications, UK, 1999.
14. Fowler, C. B., Pogozheva, I. D., Akil, H., LeVine, III, H., and Mosberg, H. I.
“Determination of the Relative Positions between TMH V and VI of the  Opioid Receptor
Using Site-Directed Mutagenesis”, in Peptides for the New Millennium, 16th American
Peptide Symposium,Fields, G. B., Tam, J. P., and Barany, G. (eds), Kluwer Academic
Publishers, Dordrecht, Netherlands, pp. 374-375 (2000).
15. LeVine, III, H. "Protein Mis-Folding and Neurodegenerative Disease: Therapeutic
Opportunities." in Drug Discovery Strategies & Techniques, Vol. 9: 245-278, Makriyannis,
A. and Biegel, D. (eds), Marcel Dekker, New York, 2003.
Harry LeVine, III
Curriculum vitae
August, 2014
16. LeVine, III, H. Ch. 12.1 “Reporters of Amyloid Structure”, in Protein Reviews series, vol.
4, Protein Misfolding, Aggregation, and Conformational Diseases, V. N. Uversky, and A. L.
Fink (eds), pp. 287-302, Kluwer Academic / Plenum Publishers, 2006.
17. LeVine, III, H. and Walker, L. C. “Chapter 11. Models of Alzheimer’s Disease”, in
Handbook of Models for Human Aging, Conn, P. M. (ed), pp. 121-134, Academic Press,
Elsevier, New York, 2006.
18. LeVine, III, H. Genetic Engineering - A Reference Handbook, 264 pp., ABC-CLIO, Santa
Barbara, CA, Second Edition, 346pp., August, 2006.
19. LeVine, III, H. Drug Discovery and Development - Technology In Transition
(undergraduate textbook), with Hugh Rang (ed), (2006), England, 346 pp., Second Edition
with R. G. Hill (ed), 345 pp., 2013, Churchill Livingstone/Harcourt Brace, London,
England. – winner of 1st prize as Medical Book of the Year in the 2006 Society of
Authors/Royals Society of Authors Medical Book Competition, and also 1st prize in the
Best Edited Book section. Highly Commended in the 2006 BMA Medical Books
competition.
20. LeVine, III, H. and Augelli-Szafran, C.E. “Chapter 4.5. Aβ Polymerization Reduction” in
Protein Folding in Neurodegenerative Diseases: Mechanisms and Therapeutic Strategies,
CRC Enzyme Inhibitors Series, H. John Smith, Claire Simons, and Robert D.E. Sewell
(eds), pp. 209-231, CRC Press, Boca Raton, FL, 2008.
21. LeVine, III, H. “Ligand Imaging of Misfolded Proteins”, in Protein Misfolding Diseases:
Current and Emerging Principles and Therapies, M. Ramirez-Alvarado, J. W. Kelly, and C.
M. Dobson, (eds), John Wiley and Sons, Ch. 30, 647-671, 2010.
22. LeVine, III, H. Medical Imaging, 211 pp, Greenwood Press/ABC-CLIO, Santa Barbara,
CA, 2010.
23. Walker, L. C., Rosen, R. F., and LeVine, III, H. “Chapter 8. Pathogenic Protein Strains as
Diagnostic and Therapeutic Targets in Alzheimer's Disease”, in Alzheimer’s Disease:
Targets for New Clinical Diagnostic and Therapeutic Strategies, Frontiers in Neuroscience
Series, A. S. Rudolph and R. D. Wegrzyn (eds), pp. 231-247, CRC Press, Boca Raton, FL,
2012.
24. Walker, L.C., Rosen, R.F., Fritz, J.J., Betarbet, R., LeVine, III, H., and Jucker, M. “Prionlike induction of Alzheimer-type proteopathy in transgenic mice”, in Prion 2010 (Conference
Proceedings), Medimond s. r. l., Bologna, Italy.
25. LeVine, III, H., Nilsson, K. P. R., and Hammarström, P. “Chapter 7. Reporters of Amyloid
Structural Polymorphism”, in Bio-nanoimaging. Protein Misfolding and Aggregation,
Uversky, V. N. and Lyubchenko, Y. L. (eds), pp. 69-79, Elsevier/Academic Press,
Waltham, MA, 2014.
Book Reviews:
1. LeVine, III, H. in American Scientist 87: 468 (1999), review of In Quest of Tomorrow's
Medicines by Jurgen Drews, David Kramer, trans., 280 pp., Springer-Verlag, 1999.
2. LeVine, III, H. in ChemMedChem 6(5): 928-939 (2011), DOI: 10.1002/cmdc.201000438,
review of Emerging Drugs and targets for Alzheimer’s Disease, Ana Martinez (ed), Vol.1
Beta-amyloid, tau protein, and glucose metabolism , 317 pp.; Vol 2. Neuronal plasticity,
neuronal protection, and other miscellaneous strategies, 301 pp.
Issued Patents:
Harry LeVine, III
1.
2.
3.
4.
Curriculum vitae
August, 2014
U. S. Patent 3,796,594 Stain Coated Slides for Differentially Staining Blood, 3/12/74
U. S. Patent 5,972,956 Inhibition of Amyloidosis by 9-Acridinones, 10/26/99.
U. S. Patent 5,955,472 Naphthylazo Inhibition of Amyloidosis, 9/21/99.
U. S. Patent 6,001,331 Method of Imaging Amyloid Deposits, 12/14/99.
Abstracts: (*Authors listed in alphabetical order)
1. LeVine, III, H., and Tsong, T.Y. "Kinetics of Co+2 Binding to Apoalkaline Phosphatase
from E. coli." Fed. Proc. 33, Abst. 76 (1974).
2. LeVine, III, H., Tsong, T.Y., and Hollis, D.P. "Some Requirements for Metal Ion Binding
to E. coli Alkaline Phosphatase and Properties of Metal Ion Hybrid Enzymes." Fed. Proc.
34, Abst. 2113 (1975).
3. Hollis, D.P., LeVine, III, H., and Nunnally, R.L. "Phosphorus NMR Studies of Alkaline
Phosphatase." Biophys. J. 16:202a (1976).
4. LeVine, III, H., Schmitges, C.J., Sahyoun, N., and Cuatrecasas, P. "Molecular Resolution
and Reconstitution of the Gpp(NH)p - and NaF - Sensitive Adenylate Cyclase System." J.
Supramolecular Structure 9 (Suppl. 2): 145 (1978).
5. Schmitges, C.J., Sahyoun, N., LeVine, III, H., Hebdon, M., and Cuatrecasas, P.
"Reconstitution of the Gpp(NH)p - and NaF - Sensitive Adenylate Cyclase System." Fed.
Proc. 37: 1537 (1978).
6. Hebdon*, M., LeVine*, III, H., Minard*, R.B., Sahyoun*, N., Schmitges, * C., and
Cuatrecasas, P. "Incorporation of Rat Brain Adenylate Cyclase into Artificial Phospholipid
Vesicles." Fed. Proc. 38: 628 (1979).
7. Sahyoun, N.E., LeVine, III, H., Schmitges, C.J., Hebdon, G.M. and Cuatrecasas, P.
"Purification of the 43,000 m.w. Adenylate Cyclase Regulatory Component and Its
Interaction with Plasma Membranes." Fed. Proc. 39: 1960 (1980).
8. Hebdon*, G.M., LeVine*, III, H., Sahyoun*, N.E., Schmitges*, C.J., Krenitsky, T.A., and
Cuatrecasas, P. "Effects of Phospholipids on Solubilized Rat Brain Adenylate Cyclase."
Fed. Proc. 39: 1987 (1980).
9. Hebdon*, G.M., LeVine*, III, H., Sahyoun*, N.E., Schmitges*, C.J., and Cuatrecasas, P.
"Role of Specific Membrane Lipids in Modulating the Activity of Adenylate Cyclase."
Biophys. J. 37: 41-42 (1982).
10. LeVine, III, H., Sahyoun, N.E., Stenbuck, P.J., and Cuatrecasas, P. "Liver Cytosolic
Activator of Adenylate Cyclase." J. Cellular Biochemistry 20: 127 (1982).
11. Sahyoun, N.E., LeVine, III, H., Khouri, R., and Cuatrecasas, P. "Purification of Two
Mitochondrial Ca+2 Uptake Activators from Liver Cytosol." Fed. Proc. 41: 1734 (1982).
12. LeVine, III, H., Sahyoun, N.E., and Cuatrecasas, P. "Drugs that Modulate Mitochondrial
Ca+2 Uptake in the Presence of Cytosolic Activators." Fed. Proc. 41: 1734 (1982).
13. Stenbuck, P.J., Sahyoun, N.E., LeVine, III, H., and Cuatrecasas, P. "Essential Component
for the Expression of Adenylate Cyclase Activity." Fed. Proc. 41: 1408 (1982).
14. LeVine, III, H., Sahyoun, N.E., Bronson, D.D., and Cuatrecasas, P. "The Major Protein
Kinase Activity for Endogenous Substrates in Neuronal Nuclei is Ca+2-CalmodulinDependent." J. Cellular Biochemistry Suppl. 8B, 111 (1984).
15. May, Jr., W.S., Sahyoun, N.E., LeVine, III, H., Jacobs, S., and Cuatrecasas, P. "Transferrin
Receptor: Regulation and Direct Phosphorylation by Calcium-Phospholipid-Dependent
Protein Kinase." Clin. Res. 32: 498A (1984).
16. Burgess, S., Sahyoun, N., Blanchard, S., LeVine, H., Chang, K., and Cuatrecasas, P.
Harry LeVine, III
Curriculum vitae
August, 2014
"Development of Protein Kinase C in Primary Neuronal Cultures." Trans. Amer. Soc. For
Neurochemistry 16: 187 (1985).
17. Wolf, M., May, S.W., LeVine, III, H., Cuatrecasas, P., and Sahyoun, N.E. "Translocation
of Protein Kinase C from the Soluble to the Membrane Bound State is Synergistically
Regulated by Ca+2 and Phorbol Esters." Fed. Proc. 44: 1420 (1985).
18. LeVine, III, H., Sahyoun, N.E., and Cuatrecasas, P. "Binding of Calmodulin to the
Neuronal Cytoskeletal Protein Kinase Cooperatively Stimulates Autophosphorylation." Fed
Proc. 44: 705. (1985).
19. LeVine, III, H., Sahyoun, N.E., and Cuatrecasas, P. "Synaptosomal Ca+2-Dependent
Phosphorylation is Cytoskeletal and Regulated by a Membrane - Bound Dephosphorylating
Activity." 13th International Congress of Biochemistry Abst. FR-343 (1985).
20. LeVine, III, H. and Sahyoun, N.E. "Biochemical and Morphological Characterization of
Free and Tubulin-Associated Forms of the Soluble Neuronal Calmodulin-Dependent Protein
Kinase II." Soc. for Neurosci. 12: Abstr. 406.8 (1986).
21. LeVine, III, H., Su, J.-L., and Sahyoun, N. "Conformational Changes Induced by Ca+2 and
Ca+2-Calmodulin Interaction with Brain Calmodulin-Dependent Protein Kinase II are
Detected with a Monoclonal Antibody." Fed. Proc. 46: 2002 (1987).
22. LeVine, III, H. "Protein Kinase C: Intracellular Signaling." Leukemia (1987).
23. Ohmstede, C.-A., LeVine, III, H., Gray, J., Huff, P.M., and Sahyoun, N.E. "Cloning of a
Novel Mr 60K Calmodulin-Binding Polypeptide with Protein Kinase Activity from Adult
Rat Brain." Soc. For Neurosci. 13: 1136 (1987).
24. LeVine, III, H., Smith, G.F.H., & Burkhart, W. "Similarity of Bovine S-Antigen and a Blue
Light - Modulated 46 kDal Substrate of a Type II Calmodulin - Dependent Protein Kinase
(PKCAM) in Drosophila Head Homogenates." Cold Spring Harbor Meeting on Molecular
Neurobiology of Drosophila (1989).
25. LeVine, III, H. "Characterization of the Phosphorylation of Drosophila Arrestins." Cold
Spring Harbor Meeting on Molecular Neurobiology of Drosophila (1991).
26. Becherer, J. D., Howe, A., Patel, I.,Wisely, B., LeVine, III, H. and McGeehan, G.
"Characterization of the Collagen and TIMP Binding Domains in Collagenase using
Truncated Enzymes and a Chimeric Matrix Metalloproteinase." J. Cellular Biochemistry
Suppl. 15G:139 (1991).
27. Hepburn, T.W., Spiegel, K., Wyborski, R., LeVine, III, H., Davis, R. "The Relationship
between the p75 and the gp140TRK Nerve Growth Factor-Binding Proteins." Keystone
Symposium on Neurodegenerative Diseases (1992).
28. Davis, R. E., Dickerson, M., Fergus, J., Hepburn, T., Hopkins, J., LeVine, III, H., Marks, J.,
Spiegel, K., Jaen, J., and Moos, W. "PD 90780: a Selective Non-Peptide Ligand for the p75
NGF Receptor." Soc. for Neurosci. Abstr. 544.4 (1992).
29. Jaen, J. C., Caprathe, B. W., Spiegel, K., Fergus, J. H., Marks, J. S., Dickerson, M. R.,
LeVine, III, H., Hepburn, T., Hopkins, J., and Davis, R. E. "Neurotrophic Factors and
Alzheimer's Disease: Discovery of Selective Non-Peptide Inhibitors of NGF-p75
Interaction." 205th ACS National Meeting, Denver, CO, March 28 - April 2, 1993, Abstract
#168.
30. Miller, S.W., Haske, T. N., and LeVine, III, H. "Inhibition of β2 - adrenergic Receptor
Desensitization." Keystone Symposium on Molecular Biology of Neuronal Signal
Transduction (1993).
31. LeVine, III, H. "Thioflavine T Forms Uniquely Fluorescent Complexes with Amyloid
Harry LeVine, III
Curriculum vitae
August, 2014
Structures of Synthetic Alzheimer's Disease β-Amyloid Peptides and Insulin in Solution."
VIIth International Symposium on Amyloidosis, Queen's University, Ontario, Canada
(1993).
32. LeVine, III, H. "Stopped-Flow Kinetics Reveal Multiple Phases of Thioflavine T Binding
to Alzheimer β(1-40) and Insulin Amyloid." Fourth International Conference on
Alzheimer's Disease and Related Disorders, Minneapolis, MN (1994).
33. LeVine, III, H., Scholten, J. and Shivers, B. D. "PD 114542 Stains Neuritic Processes in
Affected Regions of Alzheimer's Disease Brain but not in Age-Matched Control Brain."
Keystone Symposium on the Molecular and Cellular Basis of Human Neurodegenerative
Disease (1995).
34. Zhou, Z., Martins, R., LeVine, III, H., Cheetham, J., Breslow, J., Smith, J., Greengard, P.,
and Gandy, S. "Physiological Apolipoprotein Eε3 and ε4 Isoforms Promote Fibrillogenesis
of Aβ(1-42) in a Thioflavine T Assay.", Soc. for Neurosci. Abstr. 21: 1975 (1995).
35. Emmerling, M. R., LeVine, III, H., Lipinski, W., and Raby, C. "Determination of Blood
and Brain Acetylcholinesterase (AChE) Inhibition after Oral Dosing of CI-1002." Soc. for
Neurosci. Abstr. 21: 1715 (1995).
36. Haske, T., Wisniewski, H. M., Frackowiak, J.,Mazur-Kolecka, B., Kim, K. S., Mehta, P.,
Emmerling, M. R., and LeVine, III, H. "Prevalence of γ-Secretase Cleavage of βPP in
Cultured Smooth Muscle Cells.", Soc. for Neurosci. Abstr. 22: (1996).
37. Haske, T., Lynch, T., Shivers, B. D., Emmerling, M., and LeVine, III, H. "Beta-Amyloid
(1-42) Induces Apoptotic Death in Cultured Leptomeningeal Smooth Muscle Cells."
Keystone Meeting on Neurodegeneration, 1997.
38. Watson, M. D., Haske, T., Lynch, T., Barnes, L. M., LeVine, III, H., Spiegel, K., Shivers,
B., and Emmerling, M.R., "Complement Activation by Aβ 1-42 Bound to Cultured Smooth
Muscle Cells: A Possible Mechanism for Cell Death in AD Brains." Keystone Meeting on
Neurodegeneration, 1997.
39. Yan, S. D., LeVine, III, H., Soto, C., Zhu, A., Zhu, H., Roher, A., Stern, D., and Schmidt,
A. M., "RAGE and Amyloid-Beta Peptide Fibrils in Alzheimer's Disease: Cell Surface
Receptor Attracts Fibrils and Soluble Receptor Prevents Fibrillogenesis." Soc. for
Neurosci. Abstr. 23 (1997).
40. Frackowiak, J., Mazur-Kolecka, B., Krzeslowska, J., Haske, T., LeVine, III, H.,
Wisniewski, H.M. “Deposition of A in Extracellular Matrix by Cultured Myocytes.”,
Neurobiol. Aging 14:S130 (1998).
41. Mazur-Kolecka, B., Frackowiak, J., Haske, T., LeVine, III, H., Krzeslowska, J., Golabek,
A., Wisniewski, H.M., “TGF Potentiates the Intracellular Aggregation of A in Response
to Apo E: A Possible Mechanism to Form Nuclei of A Polymerization.” Neurobiol. Aging
14:S130 (1998).
42. Fowler, C. B., Pogozheva, I. D., Akil, H., LeVine, III, H., and Mosberg, H. I.,
“Determination of the Relative Positions between TMH V and VI of the  Opioid Receptor
Using Site - Directed Mutagenesis.” Proceedings of the American Peptide Symposium,
1999.
43. Haske, T., Evans, L. M., LeVine, III, H., and Emmerling, M. R. "Modulation of Secretase by HMG-CoA Reductase Inhibitors.", Soc. for Neurosci. 25: 596 (1999).
44. Haske, T., Evans, L. M., LeVine, III, H., Raby, C. A., and Emmerling, M. R. "Modulation
Of -Secretase By HMG-CoA Reductase Inhibitors." Sixth International
Stockholm/Springfield Symposium on Advances in Alzheimer's Therapy, April 5-8, 2000.
Harry LeVine, III
Curriculum vitae
August, 2014
45. LeVine, III, H. "Inhibition of A Fibrillogenesis." Sixth International
Stockholm/Springfield Symposium On Advances In Alzheimer's Therapy, April 5-8, 2000.
46. LeVine, III, H. "Bis-ANS Binds to Soluble not Fibrillar A(1-40) Peptide." World
Alzheimer Congress 2000, July 9-13, 2000.
47. LeVine, III, H. "Designing Therapeutic Amyloid Inhibitors", FASEB Summer Conference
on Amyloids and Other Protein Assembly Processes, June 11-16, 2000.
48. Glase, S., Abreo, M., Agree, C., Augelli-Szafran, C.E., Belletire, J., Emmerling, M.,
Kissinger, K., LeVine, III, H., Li, B., Lunney, B., Meng, J., Navaratnam, T., Pelletier, L.,
Rejto, P., Rowse, L., Schwarz, R., Showalter, R.,Thomson, J., Vanderpool, D., Villafranca,
E., Walker, L., and Watson, D. “Inhibitors of ERAB”. CNS Discovery Symposium, Pfizer
Global Research and Development, Groton, CT, January 19, 2001, #46.
49. Augelli-Szafran, C.E., Bian, F., Callahan, M.J., Choi, C., Feng, F., Glase, S., Graham, J.,
Lai, Y., LeVine, III, H., Lipinski, W.J., Sakkab, A., Purchase, T., and Walker, L.C. “Small
Molecule Aggregation Inhibitors of Beta Amyloid Peptide”. CNS Discovery Symposium,
Pfizer Global Research and Development, Groton, CT, January 19, 2001, #87.
50. Zhuang, N., Bigge, C. F., Barta, N., Hutchings, R. H., Shuler, K., Augelli-Szafran, C. E.,
LeVine, H., Ye, Y. “Synthesis of Substituted Indanyl Anthranilic Acid Analogs as Amyloid
Aggregation Inhibitors”, 37th Organic Symposium, Bozeman, MT, June 10-14, 2001.
51. Haske, T., Evans, L., LeVine, III, H., and Emmerling, M. “The Regulation of APP
Processing by the Modulation of the Mevalonate/Cholesterol Biosynthetic Pathway”, Third
World Congress on Vascular Factors in Alzheimer’s Disease, Kyoto, Japan, April 7-10,
2002.
52. Sakkab, A. T., Augelli-Szafran, C. E., Kimura, T., LeVine, III, H., McClure, C., Tasaki, Y.,
Yasunaga, T., and Ye, Y. “The Synthesis and Structure Activity Relationship of Substituted
Oxazolone Analogs as Amyloid Aggregation Inhibitors”, MEDI-247, ACS National
Meeting, Boston, MA, Aug. 18-22, 2002.
53. Callahan, M.J., Lipinski, W. J., Bian, F., LeVine, H., Augelli-Szafran, C. E., and Walker,
L.C. “PD 0202091, A Novel Amyloid Aggregation Inhibitor, Reduces Cerebral -Amyloid
Deposition in Tg2576 Mice”, Soc. for Neurosci. 29 (2003).
54. LeVine, III, H. “Alzheimer’s Beta-Peptide Oligomer Formation at Physiologic
Concentrations”, poster, FASEB Summer Conference on Protein Misfolding, Amyloid, And
Conformational Disease, June 12, 17, 2004, Snowmass, CO.
55. LeVine, III, H. “Alzheimer’s β-Peptide Oligomer Formation at Physiologic
Concentrations”, Poster # P1-223, 9th International Conference on Alzheimer’s Disease and
Related Disorders, July 17-22, 2004, Philadelphia, PA.
56. Augelli-Szafran, C. E., Bian, F., Callahan, M. J., Feng, R., Iwai, A., Lai, J., LeVine, III,
H., Lipinski, W., Walker, L.C., and Yasunaga, T., “PD 0118057 and PD 0202091: Small
Molecule Inhibitors of Beta Amyloid Peptide Aggregation”, 228th ACS National Meeting,
August 22-26 (2004) Philadelphia, Pennsylvania, MEDI-315.
57. Simons, L. J., Augelli-Szafran, C. E., Caprathe, B.W., Graham, J. M., Kimura, T., Lai, Y.,
LeVine, III, H., Sakkab, A. T., Tasaki, Y., Yasunaga, T., Ye, Y., Zhuang, N. “The
Synthesis and Structure Activity Relationship of Substituted N-Phenyl Anthranilic Acid
Analogs as Amyloid Aggregation Inhibitors”, 228th ACS National Meeting, August 22-26
(2004) Philadelphia, Pennsylvania, MEDI-321.
Harry LeVine, III
Curriculum vitae
August, 2014
58. Guttmann, R.P., LeVine, III, H., Estus, S., and Jafarifar, F. “Oxidative Inhibition of
Cysteine-Proteases in Alzheimer’s Disease”, Society for Neuroscience, 34th Annual
Meeting, October 23-27, 2004, San Diego, CA.
59. Silver, M. A. and LeVine, III, H. “Roles Amyloid Aβ Plays in Cellular Stress”, Abstract
744, ASBMB meeting, April, 2005, San Diego, CA.
60. Sakkab-Tan, A. T., Augelli-Szafran, S. E., Choi, C., Lai, Y., LeVine, III, H., Milbank, J.,
Orahovats, P., Yasunaga, T., and Ye, Y., “The Synthesis and Structure Activity Relationship
of Substituted Isoindoline Analogs as Amyloid Aggregation Inhibitors”, 229th ACS National
Meeting, March, 2005, San Diego, CA, MEDI-196.
61. Walker, L., Ibegbu, C., Todd, C., DeMattos, R., Smith, Y., Elfenbein, H., Stephens, S.,
Rosen, R., Warzok, R., Jucker, M., Gandy, S., LeVine, H. “Aβ-immunotherapy in a primate
model of cerebral β-amyloid angiopathy”, American Association of Neuropathologists,
June, 2005.
62. Weidner, A. M. and LeVine, III, H. “Soluble Amyloid in Human Brain Regions”, ASBMB
meeting, April 1-5, 2006, San Francisco, CA.
63. Rosen, R. F., LeVine, III, H., Murphy,M. P., Preuss, T. M., Ghiso, J. A., Farberg, A.,
Gearing, M. and Walker, L. C., “Cerebral Aβ accumulation in Alzheimer’s disease, aged
humans, and aged nonhuman primates.”, Sackler Colloquia – The New Comparative
Biology of Human Nature, National Academies Press, 2006.
64. Rosen, R. F., LeVine, III, H., Murphy, M. P., Preuss, T. M., Ghiso, J. A., Farberg, A.,
Gearing, M., and Walker, L. C., “Cerebral Aβ accumulation in Alzheimer’s disease, aged
humans, and aged nonhuman primates”, 10th International Conference on Alzheimer's
Disease and Related Disorders, July, 2006, Madrid, Spain.
65. Rosen, R.F., LeVine, III, H., Pohl, J., Reed, M., Preuss, T. M., Ghiso, J. A. ,. Tomidokoro,
Y., Rosene, D. L., Voytko, M. L., Lah, J. J., Murphy, M. P., Farberg, A., Gearing, M., and
Walker, L. C.. “Mass spectrometric detection of modified cerebral Aβ peptides in
Alzheimer's disease, aged humans, and aged nonhuman primates”, Society for
Neuroscience, 36th Annual Meeting, November, 2006, Atlanta, GA.
66. Frackowiak, J., Kaczmarski, W., Haske, T., LeVine, III, H., and Mazur-Kolecka, B.
“Extracellular matrix modifications and deposition of Aβ in cultures of vascular smooth
muscle cells”, 2nd Mediterranean Conference of Neurosciences International Brain
Research Organization, December, 2006, Marrakech, Morocco.
67. Walker, L. C., LeVine, H., Rosen, R., and Jucker, M. “The Proteopathic Basis of
Neurodegenerative Disease”, 52nd Annual Meeting of the German Society of
Neuropathology and Neuroanatomy (DGNN), September 5-8, 2007, Greifswald, Germany.
68. Rosen, R. F., Farberg, A. S., Gearing, M., LeVine III, H., Ghiso, J. A., Pruess, T.M.,
Walker. L.C. “Cerebral Aβ in humans and monkeys: in vitro and in vivo characterization”,
Abcam Molecular Mechanisms of Neurodegeneration 2007, December 3-6, 2007, Antigua.
69. Weidner, A. M. and LeVine, III, H. “Oligomeric Abeta Increases Tween 20-Insoluble MTT
in Cultured Neuroblastoma and Myoblast Cells”, 11th International Conference on
Alzheimer's Disease and Related Disorders, July 26-31, 2008, Chicago, IL.
70. LeVine, III, H. “High-Molecular Weight Macromolecular Inhibitor in Human and Animal
Brain Extracts Potently Inhibits Chaperone-Catalyzed Reactivation of Heat Denatured
Luciferase”, 11th International Conference on Alzheimer's Disease and Related Disorders,
July 26-31, 2008, Chicago, IL.
Harry LeVine, III
Curriculum vitae
August, 2014
71. LeVine, III, H., Augelli-Szafran, C. E., Voss, R. S., and Walker, J. A., “A Robotic Screen
of a Small Molecule Chemical Library for Inhibitors of Aβ Oligomer Formation”, 11th
International Conference on Alzheimer's Disease and Related Disorders, July 26-31, 2008,
Chicago, IL.
72. Rosen, R. F., LeVine, III, H., and Walker, L. C., “PIB Binding in Alzheimer’s Disease and
Nonhuman Primate Brain” 11th International Conference on Alzheimer's Disease and
Related Disorders, July 26-31, 2008, Chicago, IL.
73. Ebenezer, P. J., Weidner, A., LeVine, III, H. and Keller, J. “Aβ Oligomers Induce
Neurotoxicity: Effects of HDACs and Nrf2 Modulation”, Abst 926.7, FASEB Annual
Meeting, April 18-22, 2009, New Orleans, LA.
74. Walker, L. C., Rosen, R. F., and LeVine, III, H., “Protein aggregation in Alzheimer's
disease: Are there neurotoxic and benign Aβ strains?” Neurotoxicity Society Meeting on
Neurochemical Mechanisms for Neurodegenerative Disorders, Arica, Chile April 24-26,
2009.
75. Rosen, R. F., Ciliax, B. J., Gearing, M., Dooyema, J., Wingo, T., Lah, J. J., Ghiso, J. A.,
LeVine, III, H., and Walker, L. C., “Deficient High-Affinity Binding of Pittsburgh
Compound B in a Case of Alzheimer's Disease”, Society for Neuroscience, Chicago, IL,
October 17-21, 2009.
74. Walker, L. C., Rosen, R. F., LeVine, III, H., and Jucker, M., “Induction of Aβ deposition in
transgenic mice: Evidence for polymorphic strains”, NeuroPrion Industry Forum Fontenayaux-Roses, France, March 22, 2010.
75. Sood, A., Kulkarni, A., Borkin, D., Bag, S., Dasgupta, S., LeVine, III, H., Tӧrӧk, B., and
Tӧrӧk, M. “Structure-activity relationship of dual target inhibitors of amyloid-beta selfassembly”, ACS Fall Meeting, Boston, MA, August 22-26, 2010.
76. Beckett, T. L., Niedowicz, D. M., Matveev, S., Baig, I., LeVine, H., III, Keller, J. N., and
Murphy, M. P. “A systematic analysis of multiple Aβ pathologies in Alzheimer’s disease”,
10th International Conference on Alzheimer’s & Parkinson’s Diseases, Barcelona, Spain;
March, 2011.
77. Walker, L., Rosen, R., Dooyema, J., Cintron, A., Heuer, E., Betarbet, R., LeVine, H. III,
and Jucker, M., “Prion-Like Seeding of Cerebral Aβ Deposition in Transgenic Models of
Alzheimer-Type Proteopathy”, Keystone Conference on Neurodegenerative Diseases: The
Molecular and Cellular Basis for Neurodegeneration, Taos, NM, Feb 21-26, 2011.
78. LeVine, III, H., Matveev, S. V., Rosen, R. F., and Walker, L. C. “Neuropathology, Aβ
Conformation, and Neurotoxicity”, Neurotoxicity Society Meeting, Uspallata, Argentina,
April 7-10, 2011.
79. Walker, L. C., Rosen, R. F., Heuer, E., Cintron, A., LeVine, H., III, “Prion-like Seeding of
Cerebral Aβ Deposition in Transgenic Rodents”, Neurotoxicity Society Meeting,
Uspallata, Argentina, April 7-10, 2011.
80. Walker, L. C., LeVine, III, H., Eisele, Y. and Jucker, M. “Corruptive protein seeding in the
pathogenesis of neurodegenerative disorders”, 56th Annual Meeting German Society for
Neuropathology and Neuroanatomy, Tübingen, Germany, September 21-24, 2011.
81. Matveev, S. and LeVine, III, H., “Isolated PIB Binding Site from Human AD Brain Tissue
is a Complex of Amyloid-beta and Lipids”, Markesbery Symposium on Aging and
Dementia, University of Kentucky, Lexington, KY, October 14, 2011.
Harry LeVine, III
Curriculum vitae
August, 2014
82. Baig, I., and LeVine, III, H., “Preparation of Tau Oligomers, Tool to Study Tauopathy”,
Markesbery Symposium on Aging and Dementia, University of Kentucky, Lexington, KY,
October 14, 2011.
83. Rehak, C., Yurko, R., Izzo, N., Cromer, E., Rishton, G., Safferstein, H., Hefti, F., Miller,
M., Johanson, C., Stopa,E., Walker, L. C., LeVine, III, H., and S.M. Catalano, “Key
signaling pathways linking membrane trafficking to behavioral deficits are differentially
affected by human Alzheimer’s disease patient-derived Abeta vs. synthetic Abeta
preparations”, Society for Neuroscience, 41st Annual Meeting Washington, DC, Nov 1216, 2011.
84. Beckett, T. L., Niedowicz, D. M., Matveev, S., Baig, I., LeVine III, H., Keller, J. N., and
Murphy, M. P. “Post-Mortem Binding of Pittsburg Compound B (PiB) in Alzheimer’s
Disease Brain”, Society for Neuroscience 41st Annual Meeting, Washington, DC, Nov 1216, 2011.
85. Gosh, S., Schifone, C., Foster, M., Torok, B., LeVine, III, H., and Tӧrӧk, M. “Hydrazines
as Potential Anti-amyloidogenic Agents”, Experimental Biology, Boston, MA, Apr 20-24,
2013.
86. LeVine, III, H., Matveev, S., Sviripa, V.M, Watt, D. S., Nilsson, K. P., Hammarström, P.,
and Walker, L. C., “Mapping of Amyloid Fibril Structural Polymorphisms In Vitro, In Situ,
and In Vivo”, Bluegrass Molecular Biophysics Symposium, University of Kentucky,
Lexington, KY, May 20, 2013.
87. Chen, C., LeVine, III, H., and DeRouchey, J., “Single-Molecule Analysis of Alzheimer's βpeptide. Assembly-Disassembly at Physiological Concentration”, Bluegrass Molecular
Biophysics Symposium, University of Kentucky, Lexington, KY, May 20, 2013.
88. Matveev, S., Baig, I., Onono, F., Metts, B., Scheff, S. W., Spielmann, H. P., and LeVine,
III, H., “Composition and properties of the binding site for the amyloid imaging ligand PIB
from Alzheimer’s disease brain” Molecular and Cellular Biochemistry Department Retreat,
General Butler State Park, Carrollton, KY, June 25-26, 2013.
89. Baig, I., and LeVine, III, H., “Preparation and Characterization of Tau Oligomers. Tools to
Study Tauopathy”, Molecular and Cellular Biochemistry Department Retreat, General
Butler State Park, Carrollton, KY, June 25-26, 2013.
90. Silky, C., LeVine, III, H., Izzo, N., Rehak, C., Mozzoni, K., Yurko, R., Rishton, G.,
Safferstein, H., and Catalano, S. M., “Icelandic mutant human Abeta 42 peptide forms
less oligomers than wild-type peptide”, Society for Neuroscience, 43rd Annual Meeting,
San Diego, CA, November 9-13, 2013.
91. Ho, A. L., Chen, C., LeVine, III, H., DeRouchey, J., “Dissociation of Aβ oligomers into
monomer by DHBA determined by Fluorescence Correlation Spectroscopy (FCS)”,
Undergraduate Research in Chemistry Regional Poster Competition, University of
Kentucky, Department of Chemistry, April 18, 2014.
92. XXXXX “Pathological tau species abrogate nascent protein production by associating with
the ribosomal complex: implications of a novel tau function and its pathogenic link to
memory impairment”, Alzheimer’s Association International Conference, Copenhagen,
Denmark, July 12-17, 2014.
93. Chen, C., Gay, C., Zhang, X., LeVine, III, H., and DeRouchey, J. “Single-Molecule
Analysis of Assembly-Disassembly of Soluble Oligomeric Alzheimer's β-peptide”,
Bluegrass Molecular Biophysics Symposium, University of Kentucky, Lexington, KY, May
20, 2014.
Harry LeVine, III
Curriculum vitae
August, 2014
Recent Presentations: Since moving to the University of Kentucky in 2003
NY State Institute for Basic Research in Developmental Disabilities, Staten Island, NY, June
11, 2003 “Non-fibrillar Conformations of the Aβ Peptide”
Wayne State University, Detroit, MI, Dept. of Pharmaceutical Sciences, December 10, 2003
“Proteopathy: Protein Misfolding in Neurodegeneration”
Johns Hopkins University School of Medicine, Baltimore, NY, September 11, 2004 “Thirty
Years of Following the Science. Making it Count Against Alzheimer’s Disease”
Acumen Pharmaceuticals, South San Francisco November 17, 2004, “Conformation and
Configurations of the Alzheimer’s β-Peptide”
University of Nebraska Medical Center, January 11, 2005, “Conformations & Configurations of
the Alzheimer β-Peptide”
Morehead State, Morehead, KY, Department of Biology, March 8, 2005, “Alzheimer’s Disease:
From Causes to Cures”
University of Michigan, Dept. of Biological Chemistry, June 9, 2005 “Oligomeric Alzheimer’s
β-Peptide”
Acumen Pharmaceuticals, South San Francisco September 27, 2005, “Aβ Oligomers and
Cellular Protective Mechanisms”
Invited speaker CHI meeting on Protein Folding Disorders, Baltimore, MD, March 9, 2006,
“Effects of Intracellular Soluble Misfolded Aβ - Targets of Opportunity”
University of California-Irvine, Institute for Brain Aging and Dementia, August 22, 2006
“Strains and Stress – Conformations and Configurations of the Alzheimer’s β-Peptide”.
Emory University, School of Medicine, Center for Neurodegenerative Disease, July 16, 2007
“Amyloid Beta-peptide in the Brain: It May Not Be What You Think It Is!”
Harvard University Medical School Dept. of Neurology, LEAD Program, April 30, 2008,
“Targeting Aβ Oligomers”
Strategic Research Institute’s 10th Annual Alzheimer's Disease Research Conference, May 1-2,
2008, Boston, MA, “The Evolution of Aβ-Targeted Drug Discovery: From Fibrils to
Oligomers”.
Coins for Alzheimer Research Trust, May 6, 2009, Columbia, SC, “Molecular Basis of PIB
Binding in the AD Brain: Inducing the AD Phenotype in Neuronal Culture and TgAPP/PS1
Harry LeVine, III
Curriculum vitae
August, 2014
Mouse Brain”.
Sunrise Rotary, Lexington, KY, July 7, 2009, “Alzheimer’s Disease: Why Only Humans?”
University of British Columbia, School of Medicine, Vancouver, Canada, October 3, 2009,
“Alzheimer’s Disease: Why Only Humans?”
Department of Biophysics, Armed Forces Institute of Pathology, Rockville, MD, February 17,
2010, “Probing the Differences Between Alzheimer's disease and its Animal Models”
Louisville Rotary, Louisville, KY March 4, 2010, “Alzheimer’s Disease: Why Only Humans?”
Emory University, School of Medicine, Center for Neurodegenerative Disease, April 20, 2010,
“Reporters and Modulators of β-Amyloid Conformation”
Sanders-Brown Health and Wellness Fair, Consolidated Baptist Church, Lexington, KY, April
24, 2010, “Science at the Sanders-Brown Center on Aging”
Kentucky Association of Homes and Services for the Aging, KAHSA 2010 Conference,
Louisville, KY September 23, 2010, “Prospects and Perspectives on Alzheimer’s Disease at the
Sanders-Brown Center on Aging”
WebEdge video production for “Sanders-Brown : Research, Education/Outreach, and Clinical”
March, 2011.
V Neurotoxicity Society Meeting on Mechanisms of Aβ Toxicity, Uspallata, Mendoza,
Argentina, April 7-11, 2011, "Neuropathology, Aβ Conformation, and Neurotoxicity"
IFM Dept. of Chemistry, Linkӧping University, Linkӧping, Sweden, January 31, 2012,
“Polymorphic Forms of Aβ Assembly”
AstraZeneca AB (Sverige), Södertälje, Sweden, February 1, 2012 “Amyloid β-Peptide
Assemblies: Targets & Reporters of Disease State”
IFM Dept. of Chemistry, Linkӧping University, Linkӧping, Sweden, June 26, 2012, “Interaction
of Luminescent Conjugated Oligothiophenes with Aβ Oligomers, Fibrils, & AD Pathology”
Molecular and Cellular Biochemistry Department Retreat, General Butler State Park,
Carrollton, KY, June 25-26, 2013, “Polymorphic Human Brain β-Amyloid and Tau Pathology
in Alzheimer’s Disease”
The Process of Drug Discovery, Rancho Bernardo, San Diego, CA, October 12, 2013 “A
Unique Polymorph of Human Brain β-Amyloid Pathology in Alzheimer's Disease”
Rotary District 7670 Conference, Greenville, SC, June 20-21, 2014, “Alzheimer’s Disease: The
Upcoming Challenge to Medicine and Society”
Harry LeVine, III
Curriculum vitae
August, 2014
Research Support:
Active
Title: “AD Brain Neuronal Types Accumulating PIB-Binding Abeta”
Role: PI
Agency: Brightfocus (AHAF)
Type: Research Grant A20140445
Period: 07/01/14 – 06/30/17
Isolation of PIB binding synaptosomes from AD brain and determination of their neuron of
origin type.
Title: Biofluid Exosomes as Diagnostic Biomarkers for Alzheimer’s Disease
Role: PI
Agency: 5P30AG028383-09 Alzheimer’s Disease Center
Type: Pilot grant
Period: 7/01/14-06/30/15
Development of assay using PET imaging ligands of Aβ and tau pathology in exosomes of CSF
as diagnostic probes for AD brain pathology.
Title: “Probes to differentiate AD brain beta-amyloid from model beta-amyloid systems”
Role: co-PI (Spielmann, H. Peter co-PI)
Agency: NIH/NINDS
Type: 1R21 NS080576-01A1
Period: 7/01/13 – 06/30/15
Development and testing of photoaffinity ligands based on human specific AD β-amyloid
pathology imaging ligand Pittsburgh Compound B (PIB). These tools will be used to chemically
map the Aβ and other components of the human PIB binding site to determine differences from
the pathology of model systems.
Title: Aging of Frontal Structure and Function in Down Syndrome and Dementia
Role: Co-I; (Head, E./Schmitt, F.A. Co-PI)
Agency: NIH (NICHD/NIA)
Type: 1R01HD064993-0110
Period: 9/30/09 – 8/31/14
Determination of oligomeric and fibrillar Aβ forms in Down Syndrome brain
The proposed study will identify new ways in which to detect Alzheimer disease (AD) in adults
with Down syndrome (DS) by monitoring changes in cognitive function, measuring brain
changes by magnetic resonance imaging and profiling patterns of proteins in the plasma in
parallel with autopsy studies of brain samples.
Title: “Targeting functional assembly of the bacterial multidrug efflux transporter”
Role: co-I (Wei, Jinan PI)
Agency: NIH/NIAID
Type: 1R21AI103717-01
Period: 08/09/13 – 07/31/15
Harry LeVine, III
Curriculum vitae
August, 2014
Screening assay development for inhibitors of assembly of the AcrA-AcrB-TolC multidrug
efflux pump of Gram negative bacteria (E. coli) as a means to overcome common antibiotic
resistance.
Pending
Title: “S. aureus inorganic pyrophosphatase, a novel antimicrobial target”
Role: Co-I (Wei, Jinan PI)
Agency: NIH/NIAID
Type: R21/R33
Period: 04/01/14 – 03/31/19
Screening assay development for inhibitors of S. aureus type II inorganic pyrophosphatase as a
means to overcome common antibiotic resistance (MRSA).
In revision
Title: “Elucidation of Dissociation Mechanisms of Soluble Amyloid Protein Oligomers”
Role: co-I (DeRouchey, PI (Chemistry))
Agency: NSF PD 09-6883 (NSF-CLP)
Type: Research Grant
Period: 07/01/14 – 06/30/17
Mechanistic studies of Aβ and tau soluble oligomer stability and modulation by small molecule
ligands
In revision
Completed
Title: “Chaperone Proteins and the Metabolism of A Oligomers and Polymers”
Role: PI
Agency: NIH/NIA
Type: Alzheimer’s Disease Research Center Pilot Grant P50 under AG05144-20
Period: 05/1/03-04/30/04
Determine the interaction between Aβ and chaperone system proteins
Title: “Identifying the Disease-Associated Conformation of the Aβ Peptide in Alzheimer’s
Disease Brain”
Role: PI
Agency: office of the VP of Research, UK
Type: Faculty Research Support Grant
Period: 04/01/06-03/31/07
Establish a radioligand binding assay for a pathology related site on β-amyloid fibrils and
plaques
Title: “Chaperone-Mediated Protein Refolding Dysfunction in Alzheimer’s Disease”
Role: PI
Agency: Alzheimer’s Disease Association
Type: IIRG-06-27275
Harry LeVine, III
Curriculum vitae
August, 2014
Period: 09/01/06-08/31/09
Chaperone refolding in extracts of cells, transgenic animal model and AD brain.
Title: “A screen for small molecule inhibitors of soluble Abeta oligomer assembly”
Role: PI
Agency: NIH/NIA
Type: R21AG028816
Period: 9/01/06 – 8/31/08; no cost extensions to 8/31/10, Robotic screening of compound
libraries for inhibitors of Aβ oligomer formation
Title: “Alzheimer's Disease: Modeling Pathologic Strain-like Variants of Multimeric Aβ”
Role: Co-PI
Agency: Anonymous
Type: Research Grant
Period: 05/01/08-04/30/11
Establish proof of concept methodologies to identify and quantify the unique pathologic
strain(s) of Aβ present in AD brain to construct pathogenically valid animal models that
recapitulate the cardinal neuropathologic features of AD
Title: Use of Phage Display to Develop Biofluid PIB Binding as a Biomarker for AD
Role: PI
Agency: NIH/NIA
Type: Alzheimer’s Disease Research Center Pilot Grant P50 under AG05144-20
Period: 7/1/10 – 6/30/11
Development of tools to study the PIB imaging ligand binding site as a biofluid biomarker for
AD
Title: “Molecular Basis of PIB Binding in the AD Brain: Inducing the AD Phenotype in
Neuronal Culture and TgAPP/PS1 Mouse Brain”
Role: Co-PI
Agency: CART Foundation (Co-PI)
Period: 07/01/09-06/30/11 no cost extension to 9/30/11
Identification of PIB amyloid imaging compound binding site in AD brain and the role of Aβ
conformational variants in disease
Title: “Synthesis and analysis of agents targeting critical pathological factors in Alzheimer’s
disease brain”
Role: visiting scholar
Agency: Fulbright Scholar Program
Period: 02/01/12 – 06/30/12
Synthesis and testing of oligomer-specific and fibril ligand sub-site ligands in the laboratories of
Peter Nilsson and Per Hammarstrom at Linköping University, Linköping, Sweden
Title: Bayer-Schering Grants4Targets “Defining the AD-relevant binding site of an amyloid
ligand on polymorphic Aβ fibrils”
Role: PI
Harry LeVine, III
Curriculum vitae
August, 2014
Period: 07/01/11- 12/31/12
Patterns of polymorph-specific amyloid ligand binding sites in AD, transgenic/primate animal
models, and synthetic Aβ fibrils
Title: “Synaptic Change in Mild Cognitive Impairment”
Role: co-I (PI - Stephen W. Scheff)
Agency: NIH/NIA
Type: R01AG027219-01A1
Period: 07/01/06 – 06/30/2011, no cost extension to 4/30/2013
Determination of oligomeric and fibrillar Aβ forms in early stage Alzheimer’s disease.
The study will determine alterations in synapse number during early stage Alzheimer’s disease.
Title: “Beta amyloid and oxidative stress in Alzheimer’s disease”
Role: PI of Project 3 “Aβ and RAGE interactions in Alzheimer’s disease”; Co-PI on facility
(Core B) for production and standardization of forms of Abeta. (Linda Van Eldik-PI)
Agency: NIH/NIA
Type: 2 P01-AG005119-20
Period: 04/01/07-03/31/13 (PI - Linda Van Eldik) no-cost extension until 03/31/14
Identification of endogenous RAGE ligands in AD brain and mapping binding sites on sRAGE
Title: “Establishment of a Flow Cytometry Platform to Analyze and Isolate Synaptosomes from
AD Brain”
Role: PI
Agency: Office of the VP of Research, UK
Type: Faculty Research Support Grant
Period: 02/01/13-06/30/14
Development of procedures to characterize and isolate synaptosomes containing PIB-binding
sites to identify their neuronal source.
Students:
Former Students
Matthew A. Sanders, Department of Biology, University of Michigan - Ph.D.
awarded Winter, 1996. “Tachykinin Receptor Desensitization.”
Scott Miller, Ph. D. (Ann Arbor, MI) 1994-1996. Postdoctoral Fellow
Carol Fowler, Department of Medicinal Chemistry, School of Pharmacy, University of
Michigan, Ph.D. awarded Winter, 2002. “Testing of -Opioid Receptor Models using SiteDirected Mutagenesis and Zn+2 - Binding Site Engineering.”
Melanie A. Silver, Dept. Molecular & Cellular Biochemistry, School of Medicine, University of
Kentucky, M.S., August, 2007.
Adam M. Weidner, Dept. Molecular & Cellular Biochemistry, School of Medicine, University
of Kentucky, Ph.D., December, 2009.
Harry LeVine, III
Curriculum vitae
August, 2014
Undergraduates:
Yi Do (high school student 2 years (1992-1994) while staff member at Parke-Davis (Ann Arbor,
MI)
Two high school students, two undergraduates, two veterinary students, and two medical
students as summer interns while staff member at Burroughs-Wellcome and Glaxo in Research
Triangle Park, NC 1977-1990.
(at the University of Kentucky)
REU
Molly Housley (Centre College, KY) REU Summer Program in Structural Biology, (5/07-8/07).
Whitney Showalter (Bridgewater College, VA) REU Summer Program in Structural Biology,
(5/11-8/11).
Bio 395
Jina Amis (UK Dept. of Biology) Bio 395 Research (9/08-5/09) “PIB binding to Normal, MCI,
and AD Brain Regions”.
Barbora Krizkova (UK Dept. of Biology-University of Wolverhampton, United Kingdom
exchange student Bio 395 Research (1/09-5/09) “Aβ Oligomer Assembly Inhibitors”
Jordan Johnson (UK Dept. of Biology) Bio 395 Research (1/10-5/10) “Aβ Oligomers and the
Prion Protein”.
High School
Stephen Steinmetz (MSTC Paul Dunbar HS, Lexington, KY) (08/11 – 12/11) “Phage Display
for Phosphorylated Tau”
Rachel Armstrong (Exeter Academy (August, 2012) “High Sensitivity β-Amyloid Peptide
Quantification”
Chloe Cao (MSTC Paul Dunbar HS, Lexington, KY) (09/12 – 6/14) “Probing Effects of
Isoform and Disease-Stage Specific Phosphorylation on Assembly of the Alzheimer’s Tau
Protein”
Graduate Student Committees served:
Matthew A. Sanders (University of Michigan - Biology) Ph. D. (co-chair)
Carol Fowler (University of Michigan - Medicinal Chemistry) Ph. D. (co-chair)
William Lim (University of Michigan - Pharmacology) Ph. D. (committee member)
(at the University of Kentucky)
Rachel Ahmed (Biochemistry) M.S. (committee member)
Mary Bosserman (Biochemistry) Ph. D. (committee member)
Chen Chen (Chemistry) M.S. (committee member)
Anitha Shankara Linge Gowda (Chemistry) Ph.D. (outside examiner)
Kristi M. Green (Microbiology and Immunology) Ph. D. (committee member)
Chris Holler (Biochemistry) Ph. D. (committee member)
Smita Joel (Chemistry) Ph.D. (outside examiner)
Harry LeVine, III
Curriculum vitae
August, 2014
Levi M. Lampe (Biochemistry) (committee member)
Ganna Lyubartseva (Chemistry) Ph.D. (outside examiner)
Thomas F. Platt (Biochemistry) (committee member)
Tanea Reed (Chemistry) Ph. D. (committee member)
Eri Saijo (Microbiology/Immunology) Ph. D. (committee member)
Melanie A. Silver (Biochemistry) M.S. – chair
Sony Soman (Chemistry) (committee member)
Pauline S. Stratman (Chemistry) (committee member)
Robin L. Webb (Biochemistry) Ph.D. (committee member)
Adam M. Weidner (Biochemistry) Ph.D. co-chair
Cui Ye (Chemistry) Ph. D. (outside examiner)
(at Emory University, Atlanta, GA)
Rebecca F. Rosen (Neuroscience) Ph.D. (committee member) July, 2009
Current Student Committees:
Amaryllas F. Cintron (Neuroscience, Emory University) (committee member)
Alex Helman (Biochemistry) (committee member)
Xinyi Zhang (Chemistry) (committee member) new 2013
Other Creative Activity:
Education of the next generation of scientists begins in the elementary and secondary
schools. Some of them will become the students we teach at UK and who will enter the ranks of
academic and medical professionals. We live in a technical society and increasingly
technological world, yet many students, particularly women and minorities, lose interest early in
science and technology, and do not acquire the skills to appreciate the knowledge that opens up
a full range of careers. The system does not capture their thirst for knowledge and enthusiasm
before they decide that learning is work. This is why I write magazine articles and books for
young readers, to turn kids on to the wonders and the mysteries of science and the people who
do science. Communicating complex ideas to either juvenile or adult audiences who possess
minimal technical knowledge involves different skills than publishing a research paper or
review article. I strive to write interesting and educational pieces, not ‘dumbed down’ or ‘pop
science’. It requires recognizing where the audience is coming from and using analogy with
topics familiar to them. You are still telling a story, just as in a scientific paper.
In order to foster the important skill of communicating to this special audience, I created a
seminar course that will prepare undergraduates with an interest in science and in sharing their
knowledge with the young readers they once were to create, edit, and submit magazine articles
and books for publication. This is a course topic new to the UK Course Catalog.
Hon 252 Honors in Arts and Creativity - Creative Nonfiction - Science and Nature Writing
for Young Readers, Course Director, 2015.
Communicating the wonder of life and our universe to children in an age-appropriate
manner is an inspiring opportunity to influence future generations. Not surprisingly, doing this
Harry LeVine, III
Curriculum vitae
August, 2014
effectively requires special writing skills and a knack for explanation at just the right level for
your audience. Whether you write for magazines, books, or other materials for educational or
trade publishers, editors are looking for an engaging presentation. Narrative and stories that
convey interesting outlooks and important information grab young readers and stimulate them
to seek to learn more.
The course will provide talented motivated undergraduates who have an interest in
science and nature, but perhaps not as a career, to use their writing talents to explore
opportunities for sharing their enthusiasm with a young audience. It is designed to link
coursework in which the students have learned scientific facts and concepts at a college level to
interpret that information for non-specialists. This is a skill that will be valuable in any choice
of career path. Writing to communicate complex concepts at an age-appropriate level, with a
limited vocabulary, without dumbing down, and meeting the special challenges of engaging
young readers, all within a strictly limited wordcount are acquired skills which we will
demonstrate and practice.
LeVine – list of publications for young readers
“Summer on the Moon” for teens in CICADA magazine 5(1):54-63 (2002) is a memoir about
growing up during the Space Race, meeting astronauts, and working as an intern on SkyLab the
summer Neil Armstrong and crew landed on the Moon.
“X-treme Life” for a younger audience in CRICKET magazine, 33(10): 23-27 (2006) is about
microbial life in extreme environments on Earth and what this might tell us to expect about the
possibility of life elsewhere in our solar system.
“A Fishy Sixth Sense” ASK Magazine, 11(3): 22-27(2012) with an electricity theme, a Carus
publications science magazine for 3rd – 5th graders is about the Great White shark’s supersensitive sense of electroreception, electric eels, and fishy electrical “vision”.
The biography,“A Special Kind of Genius. Richard P. Feynman”, in CRICKET magazine 32(5):
39-44 (2005) won the 2005 Society of Children’s Book Writers and Illustrators Magazine Merit
Award for Nonfiction. Few scientists are more quirky than the physicist Richard P. Feynman,
the bongo-drumming, Nobel Prize-winning creator of Feynman Diagrams who also worked on
the atomic bomb and fingered the frozen rubber O-rings as the cause of the shuttle Challenger
explosion. His deathbed comment “This dying is boring”, encapsulates his approach to life.
This short magazine biography provided the selling point for a book-length young adult
biography The Great Explainer: The Story of Richard P. Feynman, Morgan-Reynolds
Publishing, Greensboro, NC that was published in November, 2009. Middle- and high school
students will resonate with the antics of the rambunctious teen Feynman who wanted to be part
of the crowd, but who was also determined to do things his own way.
Young adult biographies on physicists Niels Bohr and Werner Heisenberg are currently under
development.